WO2003014072A1 - Disulfide and thiosulfonate ligands and libraries comprising these ligands - Google Patents

Disulfide and thiosulfonate ligands and libraries comprising these ligands Download PDF

Info

Publication number
WO2003014072A1
WO2003014072A1 PCT/US2002/014778 US0214778W WO03014072A1 WO 2003014072 A1 WO2003014072 A1 WO 2003014072A1 US 0214778 W US0214778 W US 0214778W WO 03014072 A1 WO03014072 A1 WO 03014072A1
Authority
WO
WIPO (PCT)
Prior art keywords
aryl
heteroaryl
aliphatic
heteroaliphatic
library
Prior art date
Application number
PCT/US2002/014778
Other languages
French (fr)
Inventor
Andrew C. Braisted
Daniel A. Erlanson
Jeffrey W. Jacobs
Original Assignee
Sunesis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/990,421 external-priority patent/US6919178B2/en
Priority claimed from US10/121,216 external-priority patent/US6998233B2/en
Application filed by Sunesis Pharmaceuticals, Inc. filed Critical Sunesis Pharmaceuticals, Inc.
Priority to CA002457814A priority Critical patent/CA2457814A1/en
Priority to NZ530811A priority patent/NZ530811A/en
Priority to JP2003519022A priority patent/JP2004537594A/en
Priority to EP02746365A priority patent/EP1421063A1/en
Priority to IL15998302A priority patent/IL159983A0/en
Priority to MXPA04001074A priority patent/MXPA04001074A/en
Publication of WO2003014072A1 publication Critical patent/WO2003014072A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds

Definitions

  • the drug discovery process begins with the screening of a large number of compounds to identify modest affinity leads (K d ⁇ 1 to 10 ⁇ M).
  • An important tool in this process is the use of combinatorial libraries.
  • combinatorial methods for the generation of small molecule libraries and subsequent screening en masse have become important technologies for the identification of small molecule ligands to biological macromolecules (see, for example, Thompson et al. Chem. Rev. 1996, 96, 555-600; Balkenhohel et al. Angew. Chem. Int. Ed. Engl 1996, 35, 2288-2337; Dolle, R.E. Mol.
  • the disulfide-tethered fragments can then be identified by a variety of methods, including mass spectrometry (MS), and their affinity improved by traditional approaches upon removal of the disulfide tether. See also PCT Publication No. WO 00/00823, published on January 6, 2000 and U.S. Patent No. 6,335,155
  • Figure 1 schematically illustrates one embodiment of the tethering method.
  • Figure 2A depicts the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates with little or no binding affinity for TS.
  • Figure 2B depicts the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates where one of the ligand candidates possesses an inherent binding affinity to the enzyme.
  • Figure 3 depicts three experiments where TS is reacted with the same library pool containing the selected N-tosyl D-proline compound in the presence of increasing concentration of the reducing agent, 2-mercaptoethanol.
  • Figure 4 depicts schematically how tethering is utilized to identify a binding determinant.
  • Figure 5 depicts schematically a method where two separate tethering experiments are used to identify binding determinants that are subsequently linked together to form a conjugate molecule that binds to the target protein.
  • Figure 6 illustrates one embodiment of the tethering method using extenders.
  • the present invention expands upon the general tethering approach described above and provides novel compounds and libraries of compounds for use in this approach.
  • novel compounds and libraries described herein provide powerful tools for the development of drug leads, and are useful for the identification of fragments that bind weakly, or with moderate binding affinity, to a biological target site of interest.
  • the compounds of the invention include compounds and libraries of the general formula (I) as further defined below:
  • A is -S(CH 2 ) P R A1 or-SCO ⁇ R ⁇ , wherein p is 1-5, R A1 is -NR A3 R M ; OR ⁇ ; SR ⁇ ; -NHCOR A3 ; -NHCONR A3 R A4 ; -NR A3 R A4 R A5+ X _ , wherein X is a halogen; -COOR A3 ; CONR A3 R A4 ; -SOsR ⁇ ; -OPO 3 R A3 ; -SO 2 R A3 ; and wherein R ⁇ is an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, and each occurrence of R ⁇ , R A4 , and R A5 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety; n is 0-5;
  • L is a moiety having one of the structures:
  • each occurrence of R 1 and R 2 is independently hydrogen, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, or wherein R 1 and R 2 taken together are a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl moiety; whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
  • r is 1 or 2; and t is 0, 1 or 2.
  • compounds and libraries of special interest include
  • R ⁇ is an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, (alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety.
  • R ⁇ is methyl or phenyl.
  • R 1 and R 2 is "O ⁇ f' m or R R 4 , or wherein R 1 and R 2 taken together
  • R 1 and R 2 are each independently hydrogen or a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl moiety optionally substituted with a substituted heteroaryl moiety.
  • compounds and libraries of special interest include those compounds and libraries as generally described above, in which the substituted heteroaryl moiety has one of the structures:
  • R 9 is -COO(R 10 ), -CO(R 10 ), -CO(NR 10 R ⁇ ), -N ⁇ -NR ⁇ COR 11 , -OR 10 , or -SR 10 , wherein each occurrence of R 10 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
  • each library member has a mass that differs from another library member by at least 5 atomic mass units;
  • embodiments exclude compounds where L is , and R is any one of the following
  • R D , R E R 5 or R 6 is -SO 2 -(alkyl) or -SO 2 -
  • O i ⁇ ⁇ ⁇ R A1 embodiments exclude compounds having the structure: H 9 where
  • R A1 is NR A3 R A4 or NR A3 R A4 R A5 ⁇ -, wherein each occurrence of R 3 , R A4 and R ⁇ is hydrogen or a protecting group, and X is a halogen; and R 1 is one of the following:
  • compounds of particular interest include, among others, those which share the attributes of one or more of the foregoing subclasses. Some of those subclasses are illustrated by the following sorts of compounds:
  • R ⁇ V which :L is o and R 1 has one of the following structures:
  • R D and R G are each independently hydrogen, a protecting group, -(CR 7 R 8 ) q S(O) 2 R 5 ; or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or - (heteroaliphatic)heteroaryl moiety, and wherein each occurrence of R 5 and R 6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, - (aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or
  • R D is hydrogen, a protecting group, -(CR 7 R 8 ) q S(O) 2 R 5 ; or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, - (aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, and wherein each occurrence of R 5 and R 6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each
  • R D is a protecting group, - (CR 7 R 8 ) q S(O) 2 R 5 ' or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, - (aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, and wherein each occurrence of R 5 and R 6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the
  • Rl ⁇ V above in which L is ° , and R 1 has one of the following structures:
  • R D is hydrogen, a protecting group, - (CR 7 R 8 ) q S(O) 2 R 5 ' or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, - (aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, and wherein each occurrence of R 5 and R 6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each
  • R 1 has one of the following structures: D
  • each occurrence of R 2 , R 5 and R 6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, - (aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
  • each occurrence of R 5 and R 6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, - (aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
  • each occurrence of R 5 and R 6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, - (aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
  • R 9 is COOH or is CO(NR 10 R n ), wherein each occurrence of R 10 and R 11 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryL -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
  • Some of the foregoing compounds can exist in various isomeric forms, e.g., stereoisomers and/or diastereomers. Furthermore, certain compounds, as described herein may have one or more double bonds that can exist as either the Z or E isomer, unless otherwise indicated.
  • the invention additionally encompasses the compounds as individual isomers (e.g., as either the R or S enantiomer) substantially free of other isomers and alternatively, as mixtures of various isomers, e.g., racemic mixtures of stereoisomers.
  • this invention also encompasses pharmaceutically acceptable derivatives of these compounds and compositions comprising one or more compounds of the invention and one or more pharmaceutically acceptable excipients or additives.
  • this invention provides novel compounds and libraries of compounds useful in the drug discovery process.
  • Compounds and libraries of this invention include those specifically set forth above and described herein, and are illustrated in part by the various classes, subgenera and species disclosed elsewhere herein.
  • inventive compounds and pharmaceutical compositions thereof may be in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers.
  • certain of the compounds disclosed herein contain one or more double bonds and these double bonds can be either Z or E, unless otherwise indicated.
  • the compounds of the invention are enantiopure compounds. In certain other embodiments, a mixture of stereoisomers or diastereomers are provided.
  • the present invention provides pharmaceutically acceptable derivatives of the inventive compounds, and methods of treating a subject using these compounds, pharmaceutical compositions thereof, or either of these in combination with one or more additional therapeutic agents.
  • pharmaceutically acceptable derivative denotes any pharmaceutically acceptable salt, ester, or salt of such ester, of such compound, or any other adduct or derivative which, upon administration to a patient, is capable of providing (directly or indirectly) a compound as otherwise described herein, or a metabolite or residue thereof.
  • pro-drugs are a derivative of a compound, usually with significantly reduced pharmacological activity, which contains an additional moiety that is susceptible to removal in vivo yielding the parent molecule as the pharmacologically active species.
  • An example of a pro-drug is an ester which is cleaved in vivo to yield a compound of interest.
  • Pro-drugs of a variety of compounds, and materials and methods for derivatizing the parent compounds to create the pro-drugs are known and may be adapted to the present invention.
  • the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, the entire contents of which are incorporated herein by reference. Furthermore, it will be appreciated by one of ordinary skill in the art that the synthetic methods, as described herein, utilize a variety of protecting groups.
  • protecting group By the term “protecting group”, has used herein, it is meant that a particular functional moiety, e.g., O, S, or N, is temporarily blocked so that a reaction can be carried out selectively at another reactive site in a multifunctional compound.
  • a protecting group reacts selectively in good yield to give a protected substrate that is stable to the projected reactions; the protecting group must be selectively removed in good yield by readily available, preferably nontoxic reagents that do not attack the other functional groups; the protecting group forms an easily separable derivative (more preferably without the generation of new stereogenic centers); and the protecting group has a minimum of additional functionality to avoid further sites of reaction.
  • oxygen, sulfur, nitrogen and carbon protecting groups may be utilized.
  • oxygen protecting groups include, but are not limited to methyl ethers, substituted methyl ethers (e.g., MOM (methoxymethyl ether), MTM (methylthiomethyl ether), BOM (benzyloxymethyl ether), PMBM (p-methoxybenzyloxymethyl ether), to name a few), substituted ethyl ethers, substituted benzyl ethers, silyl ethers (e.g., TMS (trimethylsilyl ether), TES (triethylsilylether), TIPS (triisopropylsilyl ether), TBDMS (t-butyldimethylsilyl ether), tribenzyl silyl ether, TBDPS (t-butyldiphenyl silyl ether), to name a few), esters (e.g., formate, acetate, benzoate (Bz), trifluor
  • nitrogen protecting groups are utilized. These nitrogen protecting groups include, but are not limited to, carbamates (including methyl, ethyl and substituted ethyl carbamates (e.g., Troc), to name a few) amides, cyclic imide derivatives, N-Alkyl and N-Aryl amines, imine derivatives, and enamine derivatives, to name a few.
  • the phrase "protected thiol" as used herein refers to a thiol that has been reacted with a group or molecule to form a covalent bond that renders it less reactive and which may be deprotected to regenerate a free thiol.
  • the compounds, as described herein, may be substituted with any number of substituents or functional moieties.
  • substituted whether preceded by the term “optionally” or not, and substituents contained in formulas of this invention, refer to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent.
  • the substituent may be either the same or different at every position.
  • substituted is contemplated to include all permissible substituents of organic compounds.
  • the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds.
  • heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms.
  • this invention is not intended to be limited in any manner by the permissible substituents of organic compounds.
  • Combinations of substituents and variables envisioned by this invention are preferably those that result in the formation of stable compounds useful in the treatment, for example of caspase-mediated disorders, as described generally above.
  • stable as used herein, preferably refers to compounds which possess stability sufficient to allow manufacture and which maintain the integrity of the compound for a sufficient period of time to be detected and preferably for a sufficient period of time to be useful for the purposes detailed herein.
  • aliphatic includes both saturated and unsaturated, straight chain (i.e., unbranched), branched, cyclic, or polycyclic aliphatic hydrocarbons, which are optionally substituted with one or more functional groups.
  • aliphatic is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties.
  • alkyl includes straight, branched and cyclic alkyl groups.
  • alkyl alkenyl
  • alkynyl alkynyl
  • lower alkyl is used to indicate those alkyl groups (cyclic, acyclic, substituted, unsubstituted, branched or unbranched) having 1-6 carbon atoms.
  • the alkyl, alkenyl and alkynyl groups employed in the invention contain 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-6 aliphatic carbon atoms.
  • the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-4 carbon atoms.
  • Illustrative aliphatic groups thus include, but are not limited to, for example, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, -CH 2 -cyclopropyl, allyl, n-butyk sec-butyl, isobutyl, tert-butyl, cyclobutyl, -CH 2 -cyclobutyl, n-pentyl, sec-pentyl, isopentyl, tert-penryl, cyclopentyl, -CH 2 -cyclopentyl-n, hexyl, sec-hexyl, cyclohexyl, -CH 2 -cyclohexyl moieties and the like, which again, may bear one or more substituents.
  • Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, l-methyl-2-buten-l-yl, and the like.
  • Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl and the like.
  • alkoxy or "alkyloxy"
  • thioalkyl refers to an alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom or through a sulfur atom. In certain embodiments, the alkyl group contains 1-20 aliphatic carbon atoms.
  • the alkyl group contains 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl group contains 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl group contains 1-4 aliphatic carbon atoms.
  • alkoxy include but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert-butoxy, neopentoxy and n-hexoxy.
  • Examples of thioalkyl include, but are not limited to, methylthio, ethylthio, propylthio, isopropylthio, n- butylthio, and the like.
  • alkylamino refers to a group having the structure -NHR'wherein R' is alkyl, as defined herein.
  • dialkylamino refers to a group having the structure — N(R') 2 , wherein R' is alkyl, as defined herein.
  • aminoalkyl refers to a group having the structure NH 2 R'-, wherein R' is alkyl, as defined herein.
  • the alkyl group contains 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl group contains 1-10 aliphatic carbon atoms.
  • the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl group contains 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl group contains 1-4 aliphatic carbon atoms.
  • alkylamino include, but are not limited to, methylamino, ethylamino, iso-propylamino and the like.
  • substituents of the above-described aliphatic (and other) moieties of compounds of the invention include, but are not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; -OH; -NO 2 ; - CN; -CF 3 ; -CH 2 CF 3 ; -CHC1 2 ; -CH 2 OH; -CH 2 CH 2 OH; -CH 2 NH 2 ; -CH 2 SO 2 CH 3 ; -C(O)R ; - CO 2 (R); -CON(R ' ) 2 ; -OC(O)R ; -OCO 2 R ; -OCON(R) 2 ; -N
  • aryl and heteroaryl refer to stable mono- or polycyclic, heterocyclic, polycyclic, and polyheterocyclic unsaturated moieties having preferably 3-14 carbon atoms, each of which may be substituted or unsubstituted.
  • Substituents include, but are not limited to, any of the previously mentioned substitutents, i.e., the substituents recited for aliphatic moieties, or for other moieties as disclosed herein, resulting in the formation of a stable compound.
  • aryl refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl and the like.
  • heteroaryl refers to a cyclic aromatic radical having from five to ten ring atoms of which one ring atom is selected from S, O and N; zero, one or two ring atoms are additional heteroatoms independently selected from S, O and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.
  • aryl and heteroaryl groups can be unsubstituted or substituted, wherein substitution includes replacement of one or more of the hydrogen atoms thereon independently with any one or more of the following moieties including, but not limited to: aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; -OH; -NO 2 ; -CN; -CF 3 ; -CH 2 CF 3 ; -CHC1 2 ; - CH 2 OH; -CH 2 CH 2 OH; -CH 2 NH 2 ; -CH 2 SO CH 3 ; -C(O)R ; -CO 2 (R); -CON(R) 2
  • cycloalkyl refers specifically to groups having three to seven, preferably three to ten carbon atoms.
  • Suitable cycloalkyls include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like, which, as in the case of other aliphatic, heteroaliphatic or hetercyclic moieties, may optionally be substituted with substituents including, but not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; -OH; -NO 2 ; -CN; -CF 3 ; -CH 2 CF 3 ; -CHC1 2 ; - CH 2 OH; -CH 2 CH 2 OH; -CH 2 NH 2 ; -CH 2 SO 2 CH 3
  • heteroaliphatic refers to aliphatic moieties which contain one or more oxygen sulfur, nitrogen, phosphorus or silicon atoms, e.g., in place of carbon atoms. Heteroaliphatic moieties may be branched, unbranched, cyclic or acyclic and include saturated and unsaturated heterocycles such as morpholino, pyrrolidinyl, etc.
  • heteroaliphatic moieties are substituted by independent replacement of one or more of the hydrogen atoms thereon with one or more moieties including, but not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; -OH; -NO 2 ; -CN; -CF 3 ; -CH 2 CF 3 ; -CHC1 2 ; -CH 2 OH; -CH 2 CH 2 OH; -CH 2 NH 2 ; - CH 2 SO 2 CH 3 ; -C(O)R ; -C0 2 (R ); -CON(R) 2 ; -OC(O)R ; -OCO R ; -OCON(R) 2 ; -
  • any of the cycloaliphatic or heterocycloaliphatic moieties described above and herein may comprise an aryl or heteroaryl moiety fused thereto. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein.
  • haloalkyl denotes an alkyl group, as defined above, having one, two, or three halogen atoms attached thereto and is exemplified by such groups as chloromethyl, bromoethyl, trifluoromethyl, and the like.
  • heterocycloalkyl refers to a non- aromatic 5-, 6- or 7- membered ring or a polycyclic group, including, but not limited to a bi- or tr-cyclic group comprising fused six-membered rings having between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein (i) each 5- membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (ii) the nitrogen and sulfur heteroatoms may be optionally be oxidized, (iii) the nitrogen heteroatom may optionally be quatemized, and (iv) any of the above heterocyclic rings may be fused to a substituted or unsubstituted aryl or heteroaryl ring.
  • heterocycles include, but are not limited to, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl.
  • a "substituted heterocycloalkyl or heterocycle” group refers to a heterocycloalkyl or heterocycle group, as defined above, substituted by the independent replacement of one or more of the hydrogen atoms thereon with but are not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; - OH; -N0 2 ; -CN; -CF 3 ; -CH 2 CF 3 ; -CHC1 2 ; -CH 2 OH; -CH 2 CH 2 OH; -CH 2 NH 2 ; -CH 2 SO 2 CH 3 ; - C(O)R ; -CO 2 (R); -CON(
  • ligand candidate refers to a compound that possesses or has been modified to possess a reactive group that is capable of forming a covalent bond with a complimentary or compatible reactive group on a target.
  • the reactive group on either the ligand candidate or the target can be masked with, for example, a protecting group.
  • site of interest refers to any site on a target on which a ligand can bind.
  • a site of interest is any site that is outside of the primary binding site of a protein. For example, if a target is an enzyme, a site of interest is a site that is not the active site. If a target is a receptor, a site of interest is a site that is not the binding site of the receptor's ligand. '
  • target refers to a chemical or biological entity for which the binding of a ligand has an effect on the function of the target.
  • the target can be a molecule, a portion of a molecule, or an aggregate of molecules.
  • the binding of a ligand may be reversible or irreversible.
  • Specific examples of target molecules include polypeptides or proteins (e.g., enzymes, including proteases, e.g.
  • TBMs Target Biological Molecules
  • a "Target Biological Molecule” or “TBM” as used herein refers to a single biological molecule or a plurality of biological molecules capable of forming a biologically relevant complex with one another for which a small molecule agonist or antagonist has an effect on the ruction of the TBM.
  • the TBM is a protein or a portion thereof or that comprises two or more amino acids, and which possesses or is capable of being modified to possess a reactive group that is capable of forming a covalent bond with a compound having a complementary reactive group.
  • TBMs include: enzymes, receptors, transcription factors, ligands for receptors, growth factors, immunoglobulins, nuclear proteins, signal transduction components, glycoproteins, glycolipids, and other macromolecules, such as nucleic acid-protein complexes, chromatin or ribosomes, lipid bilayer-containing structures, such as membranes, or structures derived from membranes, such as vesicles.
  • the target can be obtained in a variety of ways, including isolation and purification from natural source, chemical synthesis, recombinant production and any combination of these and similar methods.
  • Preferred protein targets include: cell surface and soluble receptor proteins, such as lymphocyte cell surface receptors; enzymes; proteases (e.g., aspartyl, cysteine, metallo, and serine); steroid receptors; nuclear proteins; allosteric enzymes; clotting factors; kinases (serine/threonine kinases and tyrosine kinases); phosphatases (serine/threonine, tyrosine, and dual specificity phosphatases, especially PTP-1B, TC-PTP and LAR); thymidylate synthase; bacterial enzymes, fungal enzymes and viral enzymes (especially those associated with HIV, influenza, rhinovirus and RSV); signal transduction molecules; transcription factors; proteins or enzymes associated with DNA and/or RNA synthesis or degradation; immunoglobulins; hormones; and receptors for various cytokines.
  • cell surface and soluble receptor proteins such as lymphocyte cell surface receptors
  • enzymes proteases (e.
  • receptors include for example, erythropoietin (EPO), granulocyte colony stimulating (G-CSF) receptor, granulocyte macrophage colony stimulating (GM-CSF) receptor, thrombopoietin (TPO), interleukins, e.g.
  • EPO erythropoietin
  • G-CSF granulocyte colony stimulating
  • GM-CSF granulocyte macrophage colony stimulating
  • TPO thrombopoietin
  • interleukins e.g.
  • IGF-1 insulinlike growth factor 1
  • EGF epidermal growth factor
  • VEGF vascular endothelial growth factor
  • PLGF placental growth factor
  • TGF- ⁇ and TGF- ⁇ tissue growth factors
  • nerve growth factor nerve growth factor
  • Targets include various neurotrophins and their ligands, other hormones and receptors such as, bone morphogenic factors, follicle stimulating hormone (FSH), and luteinizing hormone (LH), CD40 ligand, apoptosis factor-1 and -2 (AP-1 and AP-2), p53, bax/bcl2, mdm2, caspases (1, 3, 8 and 9), cathepsins, IL-1 /IL-1 receptor, BACE, HIV integrase, PDE IV, Hepatitis C helicase, Hepatitis C protease, rhinovirus protease, tryptase, cPLA (cytosolic Phospholipase A2), CDK4, c-jun kinase, adaptors such as Grb2, GSK-3, AKT, MEKK-1, PAK-1, raf, TRAF's 1- 6, Tie2, ErbB 1 and 2, FGF, PDGF, PARP, CD2, C5a
  • alkyl acids, aryl acids, primary alkyl amines, secondary alkyl amines, secondary aryl amines, aldehydes and ketones can be utilized as described in more detail above and herein.
  • each of these building blocks may be purchased from a commercial source, or may be synthesized to generate a building block of particular interest.
  • building blocks that are purchased from a commercial source may also be further derivatized to generate additional diverstiy (see “1+ nub” chemistry, and the synthesis of "N-side” and "C-side” compounds and libraries as described in the exemplification herein).
  • linkers for use in the invention include, but are not limited to the following linkers shown directly below:
  • the amine linkers are generally employed for building blocks bearing a carboxylate, sulfonylchloride or isocyanate, while carboxylate linkers are generally employed for the derivatization of amines.
  • the length of the linker can be varied as necessary to sample the surface of a given protein, or more generally, of a target of interest.
  • standard coupling conditions are utilized to couple a desired building block and a desired linker as described in more detail herein.
  • these building blocks can be further derivatized to "customize" reagents, as described in more detail herein.
  • the general tethering method relies upon the formation of a covalent bond between the target and a potential ligand.
  • the covalent bond that is formed between the target and the potential ligand allows the facile determination of both binding stoichiometry and binding location.
  • the tethering method is described in U.S. Patent No. 6,335,155, PCT Publication No. WO 00/00823, and Erlanson et al, Proc. Nat. Acad. Sci. USA 97:9367-9372 (2000) which are all incorporated herein by reference and is described briefly below.
  • the compounds and libraries of compounds are useful in the above-described method.
  • a method for ligand discovery comprising: 1) contacting a target that comprises a chemically reactive group at or near a site of interest with a compound or library of compounds as described herein, which compound or library of compounds is capable of forming a covalent bond with a chemically reactive group; 2) forming a covalent bond between the target and the compound thereby forming a target-compound conjugate; and 3) identifying the target compound conjugate.
  • Figure 1 schematically illustrates one embodiment of the tethering method.
  • the target is a protein and the covalent bond is a disulfide bond.
  • a thiol- containing protein is reacted with a plurality of ligand candidates.
  • Ligand candidates are potential ligands that have been modified to include a moiety that is capable of forming a disulfide bond.
  • This moiety can be a thiol group or a masked thiol such as a disulfide of the formula -SSR where R is unsubstituted Ci-Cio aliphatic, substituted - o aliphatic, unsubstituted aryl or substituted aryl.
  • R is selected to enhance the solubility of the potential ligand candidates.
  • Illustrative examples of ligand candidates include those as described in detail above and herein.
  • ligand candidates include, but are not limited to:
  • r is 1 or 2; and t is 0, 1 or 2.
  • tethered compounds as described above may be characterized using X-ray crystallography methods.
  • X-ray crystallography as a characterization method (or other characterization methods)
  • compounds and libraries of special interest include those compounds and
  • Wn represents one of the structures having a substituted thiosulfonate moiety, which moiety, upon exposure to reducing conditions, results in homogeneous compounds: wherein r is 1 or 2; and R ⁇ 2 is an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, (alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety.
  • R ⁇ is methyl or phenyl.
  • FIG. 1B schematically illustrates the theory behind tethering.
  • a thiol- containing protein is equilibrated with at least one disulfide-containing ligand candidate, equilibrium is established between the modified and unmodified protein.
  • the reaction occurs in the presence of a reducing agent. If the ligand candidate does not have an inherent binding affinity for the target protein, the equilibrium is shifted toward the unmodified protein.
  • TS thymidylate synthase
  • DHFR dihydrofolate reductase
  • dTMP DNA base thymidine 5'-monophosphate
  • Both TS and DHRF are targets for anticancer drug development. Because the TS gene is also found in many viruses, it is also a target for development of anti-parasitic, anti- fungal, and anti-viral agents.
  • TS is an ideal validating target for several reasons. First, numerous high resolution crystal structures of various TS enzymes have been determined so that structural information can be incorporated into compound design. Second, a simple colorimetric assay exists for determining whether a potential ligand binds to TS. This assay depends on the rate of conversion of 5,10-CH ⁇ HUfolate to H 2 folate in the presence of dUMP. A second assay for binding is also spectrophotometric and relies on competition with pyridoxal-5 '-phosphate ("PLP”), which forms a complex with TS with a unique spectral signature. [0088] The TS chosen for the purposes of illustration is the E. coli TS.
  • TS enzymes Like all TS enzymes, it contains a naturally occurring cysteine residue in the active site (Cys 146) that can be used for tethering.
  • the E. coli TS includes four other cysteines but these are not conserved among other TS enzymes and are buried and thus not accessible. However, if one or more of these cysteines were reactive toward disulfides, then mutant versions of these enzymes can be used where these cysteines are mutated to another amino acid such as alanine.
  • R c is unsubstituted -Cio alkyl, substituted C C ⁇ alkyl, unsubstituted aryl, or substituted aryl, and is the variable moiety among this pool of library members.
  • Figure 2A is the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates with little or no binding affinity for TS. In the absence of any binding interactions, the equilibrium in the disulfide exchange reaction between TS and an individual ligand candidate is to the unmodified enzyme. This is schematically illustrated by the following equation.
  • the peak that corresponds to the unmodified enzyme is one of two most prominent peaks in the spectrum.
  • the other prominent peak is TS where the thiol of Cys 146 has been modified with cysteamine.
  • TS thiol of Cys 146
  • this species is not formed to a significant extent for any individual library member, the peak is due to the cumulative effect of the equilibrium reactions for each member of the library pool.
  • a thiol-containing reducing agent such as 2-mercaptoethanol
  • the active site cysteine can also be modified with the reducing agent.
  • cysteamine and 2- mercaptoethanol have similar molecular weights, their respective disulfide bonded TS enzymes are not distinguishable under the conditions used in this experiment.
  • the small peaks on the right correspond to discreet library members. Notably, none of these peaks are very prominent.
  • Figure 2A is characteristic of a spectrum where none of the ligand candidates possesses an inherent binding affinity for the target.
  • Figure 2B is the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates where one of the ligand candidates possesses an inherent binding affinity to the enzyme. As can be seen, the most prominent peak is the one that corresponds to TS where the thiol of Cys 146 has been modified with the N-tosyl-£ ) -proline compound. This peak dwarfs all others including those corresponding to the unmodified enzyme and TS where the thiol of Cysl46 has been modified with cysteamine.
  • Figure 2B is an example of a mass spectrum where tethering has captured a moiety that possesses a strong inherent binding affinity for the desired site.
  • FIG. 3 is an illustration of this phenomenon and shows three experiments where TS is reacted with the same library pool containing the selected N-tosyl-D-proline compound in the presence of increasing concentration of the reducing agent, 2-mercaptoethanol.
  • Figure 3A is the deconvoluted mass spectrum when the reaction is performed without 2-mercaptoethanol.
  • the most prominent peak corresponds to TS that has been modified with cysteamine.
  • the peak corresponding to N-tosyl-Z)-proline is nevertheless moderately selected over the other ligand candidates.
  • Figure 3B is the deconvoluted mass spectrum when the reaction is in the presence of 0.2 mM 2- mercaptoethanol.
  • the peak corresponding tosyl-D-proline is the most prominent peak and thus is strongly selected over the other ligand candidates.
  • Figure 3C is the deconvoluted mass spectrum when the reaction is in the presence of 20 mM 2-mercaptoethanol.
  • the most prominent peak under such strongly reducing conditions is the unmodified enzyme. Nevertheless, the peak corresponding to N-tosyl-E>-proline is still selected over that of the other ligand candidates in the library pool.
  • Figure 3 highlights the fact that the degree of cysteine modification in a target protein by a particular ligand candidate that possesses an inherent affinity for the target is, in part, a function of the reducing agent concentration.
  • concentration of the reducing agent used in the tethering screen can be used as a surrogate for binding affinity as well as to set a lower limit of binding affinity the ligand candidate must have to be strongly selected.
  • the tethering method can be used with a single ligand candidate or a plurality of ligand candidates.
  • the tethering method is used to screen a plurality of ligand candidates (e.g., 5, 20, 100, 500, 1000, and even >1000) to maximize throughput and efficiency.
  • a structure-activity relationship can be developed using information from a tethering experiment in much the same way SAR is developed using traditional assays. For example, ligand candidates with R c s on the left hand side of the scheme below were strongly selected against the E. coli TS but those ligand candidates with R c s on the right hand side were not.
  • the phenyl-sulfonamide core and the proline ring are essential.
  • TS appears to accommodate a great deal of flexibility around the phenyl ring where the phenyl ring can be unsubstituted or substituted with a range of groups including methyl, t- butyl, and halogen, its presence is required for selection.
  • the proline ring appears essential because compounds where it was replaced with phenylalanine, phenylglycine or pyrrole were not selected.
  • the tethering experiment is performed in the presence of a known substrate. If the selected ligand candidate possesses an inherent binding affinity for the target, it would be resistant to displacement by the substrate. In contrast, a ligand candidate that lacks an inherent binding affinity or cysteamine would be easily displaced by the substrate.
  • Another illustrative example is traditional enzymatic assays on the tether-free analog. For example, the affinity of the R c portion of the ligand fragment was determined using Michaelis-Mention kinetics. The Kj of the free acid 1 was 1.1 ⁇ 0.25 mM. Notably, the free acid competed with the natural substrate dUMP. Thus, N-tosyl-jD-proline 1 is a weak but competitive inhibitor of TS
  • X-ray crystallography was used to solve the three-dimensional structures of the native enzyme and several complexes to confirm that the information obtained from tethering can be correlated with productive binding to the target.
  • Table 1 details crystallographic data and refinement parameters.
  • One complex was of the free acid of ⁇ -tosyl-D-proline bound to TS (fourth entry in Table 1).
  • Another complex was of the ⁇ -tosyl-D-proline derivative tethered to the active site cysteine (Cys-146) (second entry in Table 1).
  • Yet another complex was of ⁇ -tosyl-D-proine derivative tethered to the C146S/L143C mutant (third entry in Table
  • Noncovalent I2 ⁇ 3 a 131.88 10 - 1.90 202,300 31,422 100 (100) 7.4 (28.2) 19.7 (3.8) 19.2 23.8 0.011 2.49
  • Glu-TP P6 3 a 126.14 c - 66.81 10 - 2.00 143,599 40,497 99.4(96.9) 8.5 (31.9) 13.9(4.0) 19.4 25.1 0.007 2.15
  • Glu-TP-ff-Ala P6 3 a - 126.03 c 66.84 10 - 1.75 142,016 58,487 95.8 (85.2) 4.0 (22.5) 17.1 (4.9) 18.0 21.4 0.007 2.00
  • the I2t3 crystal contains one monomer per asymmetric unit.
  • the P6 3 f orm contains the biologically relevant homodimer. /alues in parentheses are for the highest resolution bin. '" ⁇ » (0 - ⁇ wi
  • N-tosyl-D-proline moiety is very similar in all three cases (RMSD of 0.55 - 1.88 A, compared to 0.11 - 0.56 A for all C ⁇ carbons in the protein).
  • RMSD 0.55 - 1.88 A
  • alkyl- disulfide tethers converge onto this moiety from different cysteine residues supports the notion that the N-tosyl-D-proline moiety, not the tether, is the binding determinant.
  • tethering is a powerful method that can identify ligands that bind to a site of interest in a target.
  • Tethering can be used alone or in combination with other medicinal chemistry methods to identify and optimize a drug candidate.
  • tethering is used to identify a binding determinant (e.g. R c ) and then traditional medicinal chemistry is used to make higher affinity compounds containing the identified binding determinants or variations thereof.
  • tethering is used to both identify a binding determinant and also used to assess whether compounds containing variations of the identified binding determinants bind to the target with higher affinity.
  • tethering can be used as an alternative to traditional binding experiments where either functional assays are not available or are susceptible to artifacts. This approach is schematically illustrated in Figure 4.
  • tethering is used to identify a binding determinant R D .
  • a binding determinant is identified, traditional medicinal chemistry approaches are used to synthesize variants of R D in a modified library.
  • the modified library of ligand candidates would include variants of R D such as isosteres and homologs thereof.
  • the modified library can also include "extended" compounds that include R D or variations thereof as well as other binding determinants that can take advantage of adjacent binding regions.
  • Figure 4 illustrates a selected compound from the modified library wherein the original binding determinant R was modified to R and the selected compound includes a second binding determinant R L .
  • the Kj of compound 2 was determined to be about 55 ⁇ M and the Kj of compound
  • the method comprises: a) identifying a first compound that binds to a target protein; b) identifying a second compound that binds to the target protein; and, c) linking the first compound and second compound through a linker element to form a conjugate molecule that binds to the target protein.
  • the conjugate molecule binds to the target protein with higher binding affinity than either the first compound or second compound alone.
  • the first compound is of the formula R K SSR and the second compound is of the formula R SSR (where R" is as previously described and R ⁇ and R L are each independently C ⁇ -C 20 unsubstituted aliphatic, -C 2 o substituted aliphatic, unsubstituted aryl, or substituted aryl) and the first and second compounds bind to the target protein through a disulfide bond.
  • Figure 5 is a schematic illustration of this method where two separate tethering experiments are used to identify binding determinants R ⁇ and R L that are subsequently linked together to form a conjugate molecule that binds to the target protein.
  • the tethering experiments to identify binding determinants R ⁇ and R L occur simultaneously. In this way, it is assured that the two identified binding determinants bind to the target protein at non-overlapping sites.
  • the first compound is identified using tethering and the second compound is identified through a non-tethering method.
  • the non- tethering method comprised rational drug design and traditional medicinal chemistry.
  • the crystal structure of N-tosyl-D-proline bound to TS revealed that the tosyl group is in roughly the same position and orientation as the benzamide moiety of methylenetetrahydrofolate, the natural cofactor for the TS enzyme. Consequently, the glutamate moiety of methylenetetrahydrofoloate was grafted onto compound 1.
  • Table 2 shows a selected number of these compounds. TABLE 2
  • a variation on the tethering method for use in making and optimizing compounds
  • the method comprises: a) providing a target having a reactive nucleophile at or near a site of interest; and b) contacting the target with an extender thereby forming a target-extender complex wherein the extender comprises a first functionality that reacts with the nucleophile in the target to form a covalent bond and a second functionality that is capable of forming a disulfide bond; c) contacting the target-extender complex with a ligand candidate that is capable of forming a disulfide bond; d) forming a disulfide bond between the target-extender complex and the ligand candidate thereby forming a target-extender-ligand conjugate; and e) identifying the ligand candidate present in the target-extender-ligand conjugate.
  • a reducing agent include but are not limited to: cysteine, cysteamine, dithiothreitol, dithioerythritol, glutathione, 2-mercaptoethanol, 3- mercaptoproprionic acid, a phosphine such as tris-(2-carboxyethyl-phosphine) ("TCEP"), or sodium borohydride.
  • TCEP tris-(2-carboxyethyl-phosphine)
  • the reducing agent is 2-mercaptoethanol.
  • the reducing agent is cysteamine.
  • the reducing agent is glutathione.
  • the reducing agent is cysteine.
  • the target comprises a -SH as the reactive nucleophile and the extender comprises a first functionality that is capable of forming a covalent bond with the reactive nucleophile on the target and a second functionality that is capable of forming a disulfide bond.
  • the reactive nucleophile on the target is a naturally occurring -SH from a cysteine that is part of the naturally occurring protein sequence.
  • the reactive nucleophile on the target is an engineered -SH group where mutagenesis was used to mutate a naturally occurring amino acid to a cysteine.
  • the first and second functionalities of the extender are each independently a -SH or a masked -SH.
  • a masked thiol is a disulfide of the formula -SSR where R is as previously described.
  • the covalent bond formed between the target and the extender is a disulfide bond and thus is a reversible covalent bond.
  • the target is contacted with the extender prior to contacting the target-extender complex with one or more ligand candidates.
  • the target is contacted with a pool comprising the extender and one or more ligand candidates.
  • the first functionality is a group that is capable of forming an irreversible covalent bond with the reactive nucleophile of the target under conditions that do not denature the target and the second functionality is a -SH or a masked -SH.
  • the first functionality is a group capable of undergoing SN2-like addition.
  • extenders include: (i) ⁇ -halo acids such as
  • R is unsubstituted -C 20 aliphatic, substituted C ⁇ -C 20 aliphatic, unsubstituted aryl, and substituted aryl;
  • R' is H, -SR wherein R has been previously defined; and
  • X is a leaving group.
  • the first functionality is a group capable of undergoing SN aryl like addition.
  • suitable groups include 7-halo-2,l,3-benzoxadiazaoles, and ortho/para nitro substituted halobenzenes such as where R' and X are as previously defined.
  • the first functionality is a group capable of undergoing
  • extenders include:
  • R' is as previously defined.
  • Figure 6 illustrates one embodiment of the tethering method using extenders.
  • a target that includes a reactive nucleophile -SH is contacted with an extender comprising a first functionality X that is capable of forming a covalent bond with the reactive nucleophile and a second functionality -SR (where R is the same as R as defined above) that is capable of forming a disulfide bond.
  • a tether-extender complex is formed which is then contacted with a plurality of ligand candidates.
  • the extender provides one binding determinant (circle) and the ligand candidate provides the second binding determinant (square) and the resulting binding determinants are linked together to form a conjugate compound.
  • apoptotic target caspase-3 a member of the cysteine aspartyl protease family.
  • caspase-3 a member of the cysteine aspartyl protease family.
  • Caspases are potential drug targets for a variety of therapeutic indications involving excessive or abnormal levels of programmed cell death such as stroke, traumatic brain injury, spinal cord injury, Alzheimer's disease, Huntington's disease, Parkinson's disease, cardiovascular diseases, liver failure, and sepsis.
  • caspase-3 includes a naturally occurring cysteine residue at the active site and has been well characterized both functionally and crystallographically.
  • a suitable extender for use in the caspase-3 active site was designed using the fact that small aspartyl-based arylacyloxymethyl ketones are known to react irreversibly with the active site cysteine.
  • Two illustrative examples of suitable extenders for use with caspase-3 or other thiol proteases include compounds 13 and 14.
  • compounds 13 and 14 include an aspartic acid moiety as the binding determinant.
  • the carbonyl of the aspartic acid moiety is also part of the first functionality (the arylacyloxymethyl ketone moiety) that forms a covalent bond with the thiol of the active site cysteine.
  • Extenders 13 and 14 also include a second functionality, a masked
  • thioester in the form of a thioester that can be unmasked at the appropriate time.
  • the thioester can be converted into the free thiol by treating the target-extender complex with hydroxylamine.
  • Target-extender complexes 13' and 14' were each used in the tethering method against a library of about 10,000 ligand candidates.
  • An illustrative example of a selected ligand-candidate using target-extender complex 13' is
  • ligand candidate 15 was not selected by target-extender complex 14' and ligand candidate 16 was not selected by target-extender complex 13'. Structure-activity relationships among the selected compounds were also evident. For example, ligand candidate 17,
  • the first structure was of the conjugate that is formed when target-extender complex 13' is contacted with ligand candidate 15.
  • the second structure was of the conjugate that is formed when target-extender complex 14' is contacted with ligand candidate 16.
  • Table 3 summarizes selected crystallographic data for these structures.
  • the aspartic acid moiety of both extenders was superimposable with the aspartyl residue in a known tefrapeptide substrate.
  • the salicylate sulfonamide makes numerous contacts with the protein including four hydrogen bonds.
  • the salicylate moiety occupies the P4 pocket of the enzyme that preferentially recognizes aspartic acid in caspase-3.
  • the sulfone makes some of the same contacts as the salicylate.
  • the target-extender ligand conjugate comprises:
  • the compounds comprise the moiety
  • the compounds are of the structure:
  • Y is CH 2 , S, SO, SO 2
  • R 12 is unsubstituted aryl or substituted aryl.
  • R 12 is a unsubstituted heteroaryl or substituted heteroaryl.
  • An illustrative example of a compound of this class is compound 22 with a K; of 0.33 ⁇ M.
  • the salicylate sulfonamide-containing compounds of the present invention are additionally noteworthy. The identification of salicylate sulfonamide as a suitable P4-binding fragment would not have occurred using traditional medicinal chemistry. Using compound 21 as an example, the salicylate sulfonamide-less version of compound 21 inhibits caspase-3 with a Kj of approximately 28 ⁇ M.
  • compound I has a Kj of 0.051 ⁇ M and the addition of the salicylate sulfonamide moiety to this compound yields compound II that shows about a 300 fold decrease in binding affinity. Because of this dramatic decrease, exploring P4 binding with fripeptides would not have resulted in the identification of salicylate sulfonimide as a suitable P4-binding fragment. Yet, compounds that have this fragment available for binding to P4 are potent inhibitors. Consequently, this example highlights the power of tethering to identify important fragments that may not be found using traditional methods. As shown in the case of caspase-3, these fragments can be linked together to form powerful antagonists or agonists of a target of interest.
  • IL-2 interleukin-2
  • IL-2 is a cytokine with a predominant role in the proliferation of activated T helper lymphocytes. Mitogenic stimuli or interaction of the T cell receptor complex with antigen/MHC complexes on antigen presenting cells causes synthesis and secretion of IL-2 by the activated T cell, followed by clonal expansion of the antigen-specific cells. These effects are known as autocrine effects. In addition, IL-2 can have paracrine effects on the growth and activity of B cells and natural killer (NK) cells. These outcomes are initiated by interaction of IL-2 with its receptor on the T cell surface. Disruption of the IL-2/IL-2R interaction can suppress immune function, which has a number of clinical indications, including graft vs.
  • the compound bound to the target can be readily detected and identified by mass spectroscopy ("MS"). MS detects molecules based on mass- to-charge ratio (m/z) and can resolve molecules based on their sizes (reviewed in Yates, Trends Genet. 16: 5-8 [2000]). The target-compound conjugate can be detected directly in the MS or the target compound conjugate can be fragmented prior to detection.
  • MS mass spectroscopy
  • the compound can be liberated within the mass specfrophotometer and subsequently identified.
  • MS can be used alone or in combination with other means for detection or identifying the compounds covalently bound to the target. Further descriptions of mass spectroscopy techniques include Fitzgerald and Siuzdak, Chemistry & Biology 3: 707-715 [1996]; Chu et al, J. Am. Chem. Soc. 118: 7827-7835 [1996]; Siudzak, Proc. Natl. Acad. Sci. USA 91: 11290-11297 [1994]; Burlingame et al., Anal. Chem.
  • the target-compound conjugate can be identified using other means.
  • various chromatographic techniques such as liquid chromatography, thin layer chromatography and the like for separation of the components of the reaction mixture so as to enhance the ability to identify the covalently bound molecule.
  • Such chromatographic techniques can be employed in combination with mass spectroscopy or separate from mass spectroscopy.
  • a labeled probe fluorescently, radioactively, or otherwise
  • the formation of the new bonds liberates a labeled probe, which can then be monitored.
  • a simple functional assay such as an ELISA or enzymatic assay can also be used to detect binding when binding occurs in an area essential for what the assay measures.
  • Other techniques that may find use for identifying the organic compound bound to the target molecule include, for example, nuclear magnetic resonance (NMR), surface plasmon resonance (e.g., BIACORE), capillary electrophoresis, X-ray crystallography, and the like, all of which will be well known to those skilled in the art.
  • the methods described herein provide powerful techniques for generating drug leads, and allowing the identification of one or more fragments that bind weakly, or with moderate binding affinity, to a target at sites near one another, and the synthesis of diaphores or larger molecules comprising the identified fragments (monophores) covalently linked to each other to produce higher affinity compounds.
  • the monophores, diaphores or similar multimeric compounds including further ligand compounds are valuable tools in rational drug design, which can be further modified and optimized using medicinal chemistry approaches and structure-aided design.
  • the monophores or multiphores identified in accordance with the present invention and the modified drug leads and drugs designed therefrom can be used, for example, to regulate a variety of in vitro and in vivo biological processes which require or depend on the site-specific interaction of two molecules.
  • Molecules which bind to a polynucleotide can be used, for example, to inhibit or prevent gene activation by blocking the access of a factor needed for activation to the target gene, or repress transcription by stabilizing duplex DNA or interfering with the transcriptional machinery.
  • exemplary compounds and libraries of compounds are synthesized by coupling appropriate amine, carboxylic acid, sulfonyl chloride, etc. building blocks with appropriate linkers. Described in more detail below is the synthesis of exemplary linkers and exemplary compounds and libraries of compounds.
  • C. Generation of Building Block Diversity As discussed above, a variety of building blocks can be used to generate the tethering reagents of the invention. For example, a number of commercially available bifunctional amino acids, as shown directly below, are available for use in the present invention. It will be appreciated, however, that the building blocks to be used in the invention are not limited to these particular reagents. Additionally, these commerically available reagents can be subsequently modified to generate "customized" reagents.
  • inventive tethering reagents and libraries of reagents can be prepared using commercially available building blocks, it is also possible to "customize” these building blocks, or alternatively, develop building blocks for the development of further "customized” tethering reagents.
  • constrained amino acid described above can be further modified (for example via C- or N-side modifications as described in more detail herein) to generate additional diversity in the tethering reagents and libraries described herein.
  • Constrained amino acids in certain embodiments are utilized for their precedence in biologically active molecules and theoretical considerations (fewer rotational degrees of freedom, resist hydrophobic collapse, positional and stereochemical isomers can sample different regions of conformational space, etc.).
  • a general schematic for the N- and C-side modification of a constrained amino acid is illustrated directly below: N-side Modification C-side Modification
  • Exemplary constrained amino acid blocks include, but are not limited to:
  • Trifunctional building blocks were also considered advantageous, since the additional point of modification can allow 1) the synthesis of additional regioisomers, 2) combinatorial elaboration/refinement of a monophore hit, and 3) a potential site for recombination with other monophore hits.
  • the latter point may have particular utility with tethering, since hits obtained from different Cys mutants will by definition have their recombination nubs improperly oriented. Few constrained trifunctional building blocks are commercially available.
  • the reagents tr ⁇ r ⁇ -hydroxyproline, and R- and S-piperazine-2-carboxylic acid were available, and this list was supplemented with the unconstrained amino acids D- and L- 2,3-diaminopropionic acid (DAP), Asn, Gin, and Tyr as illustrated in the figure, below.
  • DAP unconstrained amino acids
  • Asn Asn
  • Gin Asn
  • Tyr as illustrated in the figure, below.
  • N-side modifications [00193] Selection of Reagents for "N-side" Modifications. Both the N-terminal and C- terminal sides of a constrained amino acid can be employed for the incorporation of diversity elements. Approximately 200 isocyanates and 100 sulfonylchlorides are available in reasonable quantity commercially, and these sets can be readily examined by simple inspection to select reagents. Just over 250 carboxylic acids were selected. [00194] Exemplary Core Scaffolds. Many constrained amino acid scaffolds were converted into common intermediates for tethering libraries using the scheme illustrated below. Most of these were prepared in 25 mmol quantity, which is sufficient for all 250 planned N-side modifications. [00195] Scaffold synthesis scheme:
  • AU core scaffolds were modified with the N-side diversity inputs to prepare well over 5,000 new monophores. Reactions were performed using EDC/HOBt chemistry in 8:1 DCM/DMF.
  • the vial is allowed to stand, and then the organic (bottom) layer is transferred to a new vial. This solution is then treated with saturated aqueous sodium bicarbonate, and the agitation procedure repeated.
  • a 24-well deep well filter plate is then charged with anhydrous Mg 2 S0 and placed over a rack of 24 tared, bar-coded vials.
  • the final organic layer is dispensed into the filter plate and allowed to drip into the tared vials.
  • a 1 mL DCM wash is added to the filter plate, and the combined filtrates are evaporated to dryness to complete the semi-automated work-up. Boc protection on the cystamine linker is removed with HCl/Dioxane and the vials concentrated to dryness again.
  • C-side modifications consist of the condensation of a highly diverse set of amines with conformationally-constrained core scaffolds bearing free carboxylic acids (see below).
  • the chosen amines comprise 293 inputs that were selected based upon the diversity of functionality that they display.
  • Exemplary Amine Reacations Many of the amines we wished to condense with the above scaffolds contain free hydroxyls, carboxylates, and other functionality that can afford undesired side-products if the amine were simply coupled to a core scaffold using a conventional activating agent. Alternatively, a preformed active ester can often react preferentially with the desired amine and thus minimize side-product formation. Pentafluorophenyl (pFp) esters were first tried since they are often isolated as crystalline solids yet are quite reactive. In model reactions, a representative -OpFp ester was used to acylate a cross-section of amines. Although, products were found, many reactions were incomplete (even after 24 h).
  • chemistries are chosen that are flexible such that simple variations can afford more than one class of building block.
  • Carboxylic acids are common synthons for the synthesis of heterocycles, and simple derivatives of this functional group can be combined with an elecfrophile to create a heterocycle. This is shown schematically, below:
  • Piperazines are the most common motif in the CMC and MDDR, and several N-side Nub+1 libraries have already been prepared from piperazine scaffolds. Shown below is a common intermediate that can be used in the preparation of three piperazine motifs (and their regioisomers), including forms which will ultimately display a basic amine (Boc- protected), a tertiary amine (N-methyl) and an amide (N-acetyl). These three motifs represent fragments of the most common forms of derivatization for this core scaffold. Each of these can be made from the indicated Boc/Fmoc intermediate. After much experimentation, we have devised an efficient two step procedure for the preparation of this intermediate, and over 50 g are currently in-house. Each piperazine motif will be systematically prepared and derivatized using the "Go To" amine set.
  • Oxazoles are also a common motif. A variety of oxazoles were prepared from conformationally constrained amino acids and serine using the route shown below:
  • Example 1 Library 000004 consists of 484 peptidomimetic compounds connected to the cystamine-derived tethering linker. This library consists of four conformationally constrained amino acid "scaffolds" that were acylated with 121 different carboxylic acids. General formula for the library is as follows:
  • Example 2 Library 000005 consists of 453 peptidomimetic compounds connected to the cystamine-derived tethering linker. This library consists of four conformationally-constrained amino acid "scaffolds" that were acylated with 121 different carboxylic acids. General formula for the library is as follows:
  • R' is defined as for R 5 and R 6 , as described generally herein.
  • Example 3 Library 000006 consists of 453 peptidomimetic compounds connected to the cystamine-derived tethering linker. This library consists of four conformationally-consfrained amino acid "scaffolds" that were acylated with 121 different carboxylic acids. General formula for the library is as follows:
  • Example 4 Library 000007 consists of 681 peptidomimetic compounds connected to the cystamine-derived tethering linker. This library consists of six conformationally-constrained amino acid "scaffolds" that were acylated with 121 different carboxylic acids. General formula for the library is as follows:
  • R' is defined as for R 5 and R , as described generally herein.
  • Example 5 Library 000014 was prepared from four conformationally- constrained amino acid "scaffolds" that were used to acylated 293 diverse primary and secondary amines (1172 reactions). After eliminating compounds that failed QC, 690 compounds were released.
  • General formula for the library is as follows:
  • Example 6 Library 000017 was prepared from 10 conformationally-consfrained amino acid "scaffolds" that were used to acylate 220 diverse primary and secondary amines (approx. 2200 reactions). After eliminating compounds that failed QC, 833 compounds were released.
  • General formula for the library is as follows: Scaffolds Boc*
  • Example 7 Library 000018 was prepared from 9 conformationally-constrained amino acid "scaffolds" that were used to acylate 220 diverse primary and secondary amines (approx. 2000 reactions). After eliminating compounds that failed QC, 811 compounds were released.
  • General formula for the library is as follows:
  • Example 8 Library 000016 was prepared from five thiazole core scaffolds, that were used to acylated 220 diverse primary and secondary amines (1100 reactions). 750 of these passed QC and were added to the screening collection. ids,
  • MS mass spectroscopy
  • a mass spectrometer first converts molecules into gas-phase ions, then individual ions are separated on the basis of m/z ratios and are finally detected.
  • a mass analyzer which is an integral part of a mass spectrometer, uses a physical property (e.g. electric or magnetic fields, or time-of-flight [TOF]) to separate ions of a particular m/z value that then strikes the ion detector.
  • a physical property e.g. electric or magnetic fields, or time-of-flight [TOF]
  • Mass spectrometers are capable of generating data quickly and thus have a great potential for high-throughput analysis.
  • MS offers a very versatile tool that can be used for drug discovery.
  • Mass spectroscopy may be employed either alone or in combination with other means for detection or identifying the organic compound ligand bound to the target.
  • Techniques employing mass spectroscopy are well known in the art and have been employed for a variety of applications (see, e.g., Fitzgerald and Siuzdak, Chemistry & Biology 3: 707- 715 [1996]; Chu et al, J. Am. Chem. Soc. 118: 7827-7835 [1996]; Siudzak, Proc. Natl. Acad. Sci.
  • NMR nuclear magnetic resonance
  • capillary electrophoresis capillary electrophoresis
  • X-ray crystallography X-ray crystallography

Abstract

The present invention provides compounds and libraries of compounds having formula (I), wherein L and n are defined as in the claims and A is -S(CH2)pRA1 or -S(O)¿2R?A2 with p, R?A1 and RA2¿ as defined in the claims. The libraries comprising compounds of formula (I) are useful in the drug discovery process.

Description

DISULFIDE AND THIOSULFONATE LIGANDS AND LIBRARIES COMPRISING THESE LIGANDS
PRIORITY INFORMATION [0001] This application asserts priority to U.S. Serial No. 10/121,216 filed April 10, 2002; U.S. Serial No. 09/990,421 filed November 21, 2001; and U.S. Serial No. 60/310,725 filed August 7, 2001.
BACKGROUND OF THE INVENTION [0002] In general, the drug discovery process begins with the screening of a large number of compounds to identify modest affinity leads (Kd ~1 to 10 μM). An important tool in this process is the use of combinatorial libraries. Specifically, combinatorial methods for the generation of small molecule libraries and subsequent screening en masse have become important technologies for the identification of small molecule ligands to biological macromolecules (see, for example, Thompson et al. Chem. Rev. 1996, 96, 555-600; Balkenhohel et al. Angew. Chem. Int. Ed. Engl 1996, 35, 2288-2337; Dolle, R.E. Mol. Diversity 1998, 3, 199-233; and Dolle et l. J. Comb. Chem. 1999, 1, 235-282). [0003] Clearly, the ligands that are identified using this process serve as powerful tools for pharmacological studies and for drug development. The most successful libraries to date have been those based upon specific information such as knowledge of the mechanism or structure of the biological target, or by basing the library upon lead compounds that have been previously identified to bind to a target (see, for example, Kick et al. Chem. Biol. 1997, 4, 297-307; Rockwell et al. J. Am. Chem. Soc. 1996, 118, 10337-10338; Gray et al. Science 1998, 281, 533-538; Yang et al. Proc. Natl. Acad. Sci. USA 1998, 95, 10836-10841; Rohrer et al. Science 1998, 282, 737-740).
" [0004] Unfortunately, although some targets are well suited for this screening process, most are problematic because moderate affinity leads are difficult to obtain. Identifying and subsequently optimizing weaker binding compounds would improve the success rate, but this would necessitate screening at higher concentrations and screening at high concentrations is generally impractical because of compound insolubility and assay artifacts. Moreover, the typical screening process does not target specific sites for drug design, only those sites for which a high-throughput assay is available. Finally, many traditional screening methods rely on inhibition assays that are often subject to artifacts caused by reactive chemical species or denaturants. [0005] Erlanson et al, Proc. Nat. Acad Sci. USA 2000, 97, 9367-9372, have recently reported a new strategy, called "tethering", to rapidly and reliably identify small (~250 Da) soluble drug fragments that bind with low affinity to a specifically targeted site on a protein or other macromolecule, using an intermediary disulfide "tether." According to this approach, a library of disulfide-containing molecules is allowed to react with a cysteine- containing target protein under partially reducing conditions that promote rapid thiol exchange. If a molecule has even weak affinity for the target protein, the disulfide bond ("tether") linking the molecule to the target protein will be entropically stabilized. The disulfide-tethered fragments can then be identified by a variety of methods, including mass spectrometry (MS), and their affinity improved by traditional approaches upon removal of the disulfide tether. See also PCT Publication No. WO 00/00823, published on January 6, 2000 and U.S. Patent No. 6,335,155
[0006] So that the potential of the tethering method can be more fully realized, there remains a need to expand upon the libraries of compounds that are amenable for use with this approach. Among other things, the present invention provides such libraries.
DESCRIPTION OF THE FIGURES [0007] Figure 1 schematically illustrates one embodiment of the tethering method. [0008] Figure 2A depicts the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates with little or no binding affinity for TS. [0009] Figure 2B depicts the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates where one of the ligand candidates possesses an inherent binding affinity to the enzyme.
[0010] Figure 3 depicts three experiments where TS is reacted with the same library pool containing the selected N-tosyl D-proline compound in the presence of increasing concentration of the reducing agent, 2-mercaptoethanol.
[0011] Figure 4 depicts schematically how tethering is utilized to identify a binding determinant.
[0012] Figure 5 depicts schematically a method where two separate tethering experiments are used to identify binding determinants that are subsequently linked together to form a conjugate molecule that binds to the target protein. [0013] Figure 6 illustrates one embodiment of the tethering method using extenders.
DESCRIPTION OF THE INVENTION [0014] As described above, there remains a need to accelerate the drug discovery process. In general, the present invention expands upon the general tethering approach described above and provides novel compounds and libraries of compounds for use in this approach. Specifically, the novel compounds and libraries described herein provide powerful tools for the development of drug leads, and are useful for the identification of fragments that bind weakly, or with moderate binding affinity, to a biological target site of interest.
[0015] 1) General Description of Compounds and Libraries of the Invention
[0016] The compounds of the invention include compounds and libraries of the general formula (I) as further defined below:
(I)
wherein A is -S(CH2)PRA1 or-SCO^R^, wherein p is 1-5, RA1 is -NRA3RM; OR^; SR^; -NHCORA3; -NHCONRA3RA4; -NRA3RA4RA5+X_, wherein X is a halogen; -COORA3; CONRA3RA4; -SOsR^; -OPO3RA3; -SO2RA3; and wherein Rω is an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, and each occurrence of R^, RA4, and RA5 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety; n is 0-5;
L is a moiety having one of the structures:
Figure imgf000006_0001
each occurrence of R1 and R2 is independently hydrogen, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, or wherein R1 and R2 taken together are a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl moiety; whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
[0017] It will be appreciated that for compounds and libraries as generally described above, certain classes of compounds and libraries of special interest include those in which L is one of the following structures:
Figure imgf000006_0002
wherein R1 and R2 are each described generally above and in exemplary embodiments herein. [0018] In certain other embodiments, compounds and libraries of special interest include
those compounds and libraries wherein W n represents one of the structures:
Figure imgf000007_0001
wherein r is 1 or 2; and t is 0, 1 or 2.
[0019] In certain other embodiments, compounds and libraries of special interest include
those compounds and libraries wherein W n represents one of the structures:
Figure imgf000007_0002
wherein r is 1 or 2; and R^ is an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, (alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety. [0020] In certain embodiments of special interest for the compounds described directly above, R^ is methyl or phenyl.
[0021] In yet other embodiments, certain classes of compounds and libraries of special
Figure imgf000008_0001
or wherein R and R taken together form a cyclic moiety having the structure: wherein B-D, D-E, E-G, G-J, two or more occurrences of J, and J-B are each independently joined by a single or double bond as valency and stability permit, wherein B is N, CH or C, D is -NRD-, =N-, -O-, -CHRD-, or =CRD-, E is -NRE-, =N-, -O-, -CHRE-, or =CRE-, G is -NRG-, =N-, -0-, -CHRG-, or =CRG-, each occurrence of J is independently - NRJ-, =N-, -O-,-CHRJ-, or =CRJ-5 m is 0-4 and p is 0-4, each occurrence of R3, R4, RD, RE, RG and RJ is independently hydrogen, a protecting group, -(CR7R8)qNR5R6, -(CR7R8)qOR5, -(CR7R8)qSR5, -(CR7R8)q(C=O)R5, - (CR7R8)q(C=O)OR5; -(CR7R8)q(C=O)NR5R6, -(CR7R8)qS(O)2R5, -(CR7R8)qNR5(C=O)R6, - (CR7R8)qNR5(C=O)OR6,- (CR7R8)qS(O)2NR5R6, -(CR7R8)qNRsS(0)2R6, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, q is 0-4; and each occurrence of R5, R6, R7 and Rs is independently hydrogen, a protecting group, or an aliphatic, heteroalipahtic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroalipahtic)aryl, or -(heteroaliphatic)heteroaryl moiety; whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
[0022] In still other embodiments, certain classes of compounds and libraries of special
RlγV interest include those compounds and libraries in which L is o and R1 is -OJfm or R ; wherein m is 0-4, p is 0-4, D is CHRD or NRD, G is CHRG or NRG and each occurrence of J is independently CHRJ or NRJ, wherein each occurrence of RD, RE RG RJ, R3, and R4 is independently hydrogen, a protecting group, -(CR7R8)qNR5R6, - (CR7R8)qOR5, -(CR7R8)qSR5, -(CR7R8)q(C=O)R5, -(CR7R8)q(C=O)NR5R6, -(CR7R8)qS(O)2R5, -(CR7R8)qNR5(C=O)R6, -(CR7R8)qS(O)2NR5R6, -(CR7R8)qNR5S(O)2R6, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, wherein q is 0-4; and wherein each occurrence of R5, R6, R7 and R8 is independently hydrogen, a protecting group, or an aliphatic, heteroalipahtic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroalipahtic)aryl, or - (heteroaliphatic)heteroaryl moiety; whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
[0023] In yet other embodiments, certain classes of compounds and libraries of special
interest include those compounds and libraries in which L is
Figure imgf000009_0001
is one of the structures:
Figure imgf000010_0001
[0024] In still other embodiments, compounds and libraries of special interest include
those compounds and libraries as generally described above, in which L is
Figure imgf000010_0002
and
one or both of R1 and R2 is "O ~~^f'm or R R4 , or wherein R1 and R2 taken together
with N form a cyclic structure: m ; wherein N-D, D-E, E-G, G-J, two or more occurrences of J, and J-N are each independently joined by a single or double bond as valency and stability permit, wherein D is -NRD-, =N-, -O-, -CHRD-, or =CRD-, E is -NRE-, =N-, -O-, -CHRE-, or =CRE-, G is -NRG-, =N-, -O-, -CHRG-, or =CRG-, each occurrence of J is independently -NRJ-, =N-, -O-,-CHRJ-, or =CRJ-; m is 0-4 and p is 0-4, each occurrence of R3, R4, RD, R , R and RJ is independently hydrogen, a protecting group, -(CR7R8)qNR5R6, -(CR7R8)qOR5, -(CR7R8)qSRs, -(CR7R8)q(C=O)R5, - (CR7R8)q(C=O)OR5; -(CR7R8)q(C=O)NR5R6, -(CR7R8)q; -S(O)2R5(CR7R8)qNR5(OO)R6, - (CR7R8)qNR5(C=O)OR6,- (CR7R8)qS(O)2NR5R6, -(CR7R8)qNR5S(O)2R6, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, q is 0-4; and each occurrence of R5, R6, R7 and R8 is independently hydrogen, a protecting group, or an aliphatic, heteroalipahtic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroalipahtic)aryl, or -(heteroaliphatic)heteroaryl moiety; whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
[0025] In yet other embodiments, compounds and libraries of special interest include
R1
those compounds and libraries as generally described above, in which L is ° and one or both of R1 and R2 is a moiety having one of the following structures, or wherein R1 and R2 taken together with N form a cyclic moiety having one of the following structures:
Figure imgf000012_0001
[0026] In still other embodiments, compounds and libraries of special interest include
those compounds and libraries as generally described above, in which L is
Figure imgf000012_0002
, and
R1 and R2 are each independently hydrogen or a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl moiety optionally substituted with a substituted heteroaryl moiety.
[0027] In still other embodiments, compounds and libraries of special interest include those compounds and libraries as generally described above, in which the substituted heteroaryl moiety has one of the structures:
Figure imgf000013_0001
wherein R9 is -COO(R10), -CO(R10), -CO(NR10Rπ), -NΛ^-NR^COR11, -OR10, or -SR10, wherein each occurrence of R10 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
[0028] A number of important subclasses of each of the foregoing classes deserve separate mention; these subclasses include subclasses of the foregoing classes in which:
[0029] i) libraries of compounds as described directly above in which the library comprises at least 5 members;
[0030] ii) libraries of compounds as described generally above in which the library comprises at least 20 members;
[0031] iii) libraries of compounds as described generally above in which the library comprises at least 100 members;
[0032] iv) libraries of compounds as described generally above in which the library comprises at least 500 members;
[0033] v) libraries of compounds as described generally above in which the library comprises at least 1000 members;
[0034] vi) libraries of compounds as described generally above in which each library member has a different molecular weight;
[0035] vii) libraries of compounds as described generally above in which each library member has a mass that differs from another library member by at least 5 atomic mass units; and
[0036] viii) libraries of compounds as described generally above in which each library member has a mass that differs from another library member by at least 10 atomic mass units; [0037] ix) compounds and libraries of compounds, as described herein, in certain
embodiments exclude compounds where L is
Figure imgf000014_0001
, and R is any one of the following
structures:
Figure imgf000014_0002
; wherein AR is substituted or unsubstituted ary 1 or heteroaryl;
[0038] x) compounds and libraries of compounds, as described herein, in certain
embodiments exclude compounds where L is
Figure imgf000014_0003
structures:
Figure imgf000014_0004
; wherein AR is substituted or unsubstituted aryl or heteroaryl, and at least one of RD, RE R5 or R6 is -SO2-(alkyl) or -SO2-
(aryl);
[0039] compounds and libraries of compounds, as described herein, in certain
O i ^ ς ^ RA1 embodiments exclude compounds having the structure: H 9 where
RA1 is NRA3RA4 or NRA3RA4RA5χ-, wherein each occurrence of R 3, RA4 and R^ is hydrogen or a protecting group, and X is a halogen; and R1 is one of the following:
Figure imgf000014_0005
[0040] As the reader will appreciate, compounds of particular interest include, among others, those which share the attributes of one or more of the foregoing subclasses. Some of those subclasses are illustrated by the following sorts of compounds:
[0041] I) Compounds and Libraries of compounds of formula (I) described above in
RγV which :L is o and R1 has one of the following structures:
Figure imgf000015_0001
In certain embodiments of special interest, RD and RG are each independently hydrogen, a protecting group, -(CR7R8)qS(O)2R5 ; or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or - (heteroaliphatic)heteroaryl moiety, and wherein each occurrence of R5 and R6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, - (aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
[0042] II) Compounds and Libraries of compounds of formula (I) described
RγV above in which L is o , and R1 has one of the following structures:
Figure imgf000015_0002
In certain embodiments of special interest, RD is hydrogen, a protecting group, -(CR7R8)qS(O)2R5 ; or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, - (aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, and wherein each occurrence of R5 and R6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
[0043] III) Compounds and Libraries of compounds of formula (I) described
Figure imgf000016_0001
above in which L is o 5 and R1 has one of the following structures:
Figure imgf000016_0002
In certain embodiments of special interest, RD is a protecting group, - (CR7R8)qS(O)2R5 ' or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, - (aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, and wherein each occurrence of R5 and R6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
[0044] IV) Compounds and Libraries of compounds of formula (I) described
RlγV above in which L is ° , and R1 has one of the following structures:
Figure imgf000017_0001
In certain embodiments of special interest, RD is hydrogen, a protecting group, - (CR7R8)qS(O)2R5 ' or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, - (aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, and wherein each occurrence of R5 and R6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
[0045] V) Compounds and Libraries of compounds of formula (I) described
above in which L is
Figure imgf000017_0002
, and R1 has one of the following structures: D
Figure imgf000017_0003
In certain embodiments of special interest, each occurrence of R2, R5 and R6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, - (aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted. [0046] VI) Compounds and Libraries of compounds of formula (I) described
above in which L is 'Y ° 1- , and R is one of the following structures:
Figure imgf000018_0001
In certain embodiments of special interest, each occurrence of R5 and R6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, - (aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
[0047] VI) Compounds and Libraries of compounds of formula (I) described
above in which L is
Figure imgf000018_0002
Figure imgf000019_0001
In certain embodiments of special interest, each occurrence of R5 and R6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, - (aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
[0048] VII) Compounds and Libraries of compounds of formula (I) described above in which wherein R1 and R2 represent one of the following structures:
Figure imgf000019_0002
wherein R9 is COOH or is CO(NR10Rn), wherein each occurrence of R10 and R11 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryL -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
[0049] It will also be appreciated that for each of the subgroups I- VII described above, a variety of other subclasses are of special interest, including, but not limited to those classes described above i)-xi) and classes, subclasses and species of compounds described above and in the examples herein.
[0050] Some of the foregoing compounds can exist in various isomeric forms, e.g., stereoisomers and/or diastereomers. Furthermore, certain compounds, as described herein may have one or more double bonds that can exist as either the Z or E isomer, unless otherwise indicated. The invention additionally encompasses the compounds as individual isomers (e.g., as either the R or S enantiomer) substantially free of other isomers and alternatively, as mixtures of various isomers, e.g., racemic mixtures of stereoisomers. In addition to the above-mentioned compounds per se, this invention also encompasses pharmaceutically acceptable derivatives of these compounds and compositions comprising one or more compounds of the invention and one or more pharmaceutically acceptable excipients or additives.
[0051] 2) Compounds and Definitions
[0052] As discussed above, this invention provides novel compounds and libraries of compounds useful in the drug discovery process. Compounds and libraries of this invention include those specifically set forth above and described herein, and are illustrated in part by the various classes, subgenera and species disclosed elsewhere herein. [0053] It will be appreciated by one of ordinary skill in the art that asymmetric centers may exist in the compounds of the present invention. Thus, inventive compounds and pharmaceutical compositions thereof may be in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers. Furthermore, it will be appreciated that certain of the compounds disclosed herein contain one or more double bonds and these double bonds can be either Z or E, unless otherwise indicated. In certain embodiments, the compounds of the invention are enantiopure compounds. In certain other embodiments, a mixture of stereoisomers or diastereomers are provided. [0054] Additionally, the present invention provides pharmaceutically acceptable derivatives of the inventive compounds, and methods of treating a subject using these compounds, pharmaceutical compositions thereof, or either of these in combination with one or more additional therapeutic agents. The phrase, "pharmaceutically acceptable derivative", as used herein, denotes any pharmaceutically acceptable salt, ester, or salt of such ester, of such compound, or any other adduct or derivative which, upon administration to a patient, is capable of providing (directly or indirectly) a compound as otherwise described herein, or a metabolite or residue thereof. Pharmaceutically acceptable derivatives thus include among others pro-drugs. A pro-drug is a derivative of a compound, usually with significantly reduced pharmacological activity, which contains an additional moiety that is susceptible to removal in vivo yielding the parent molecule as the pharmacologically active species. An example of a pro-drug is an ester which is cleaved in vivo to yield a compound of interest. Pro-drugs of a variety of compounds, and materials and methods for derivatizing the parent compounds to create the pro-drugs, are known and may be adapted to the present invention. [0055] Certain compounds of the present invention, and definitions of specific functional groups are also described in more detail below. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, the entire contents of which are incorporated herein by reference. Furthermore, it will be appreciated by one of ordinary skill in the art that the synthetic methods, as described herein, utilize a variety of protecting groups. By the term "protecting group", has used herein, it is meant that a particular functional moiety, e.g., O, S, or N, is temporarily blocked so that a reaction can be carried out selectively at another reactive site in a multifunctional compound. In preferred embodiments, a protecting group reacts selectively in good yield to give a protected substrate that is stable to the projected reactions; the protecting group must be selectively removed in good yield by readily available, preferably nontoxic reagents that do not attack the other functional groups; the protecting group forms an easily separable derivative (more preferably without the generation of new stereogenic centers); and the protecting group has a minimum of additional functionality to avoid further sites of reaction. As detailed herein, oxygen, sulfur, nitrogen and carbon protecting groups may be utilized. For example, in certain embodiments, as detailed herein, certain exemplary oxygen protecting groups are utilized. These oxygen protecting groups include, but are not limited to methyl ethers, substituted methyl ethers (e.g., MOM (methoxymethyl ether), MTM (methylthiomethyl ether), BOM (benzyloxymethyl ether), PMBM (p-methoxybenzyloxymethyl ether), to name a few), substituted ethyl ethers, substituted benzyl ethers, silyl ethers (e.g., TMS (trimethylsilyl ether), TES (triethylsilylether), TIPS (triisopropylsilyl ether), TBDMS (t-butyldimethylsilyl ether), tribenzyl silyl ether, TBDPS (t-butyldiphenyl silyl ether), to name a few), esters (e.g., formate, acetate, benzoate (Bz), trifluoroacetate, dichloroacetate, to name a few), carbonates, cyclic acetals and ketals. In certain other exemplary embodiments, nitrogen protecting groups are utilized. These nitrogen protecting groups include, but are not limited to, carbamates (including methyl, ethyl and substituted ethyl carbamates (e.g., Troc), to name a few) amides, cyclic imide derivatives, N-Alkyl and N-Aryl amines, imine derivatives, and enamine derivatives, to name a few. The phrase "protected thiol" as used herein refers to a thiol that has been reacted with a group or molecule to form a covalent bond that renders it less reactive and which may be deprotected to regenerate a free thiol. Certain other exemplary protecting groups are detailed herein, however, it will be appreciated that the present invention is not intended to be limited to these protecting groups; rather, a variety of additional equivalent protecting groups can be readily identified using the above criteria and utilized in the present invention. Additionally, a variety of protecting groups are described in "Protective Groups in Organic Synthesis" Third Ed. Greene, T.W. and Wuts, P.G., Eds., John Wiley & Sons, New York: 1999, the entire contents of which are hereby incoφorated by reference.
[0056] It will be appreciated that the compounds, as described herein, may be substituted with any number of substituents or functional moieties. In general, the term "substituted" whether preceded by the term "optionally" or not, and substituents contained in formulas of this invention, refer to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. When more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. As used herein, the term "substituted" is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms. Furthermore, this invention is not intended to be limited in any manner by the permissible substituents of organic compounds. Combinations of substituents and variables envisioned by this invention are preferably those that result in the formation of stable compounds useful in the treatment, for example of caspase-mediated disorders, as described generally above. The term "stable", as used herein, preferably refers to compounds which possess stability sufficient to allow manufacture and which maintain the integrity of the compound for a sufficient period of time to be detected and preferably for a sufficient period of time to be useful for the purposes detailed herein.
[0057] The term "aliphatic", as used herein, includes both saturated and unsaturated, straight chain (i.e., unbranched), branched, cyclic, or polycyclic aliphatic hydrocarbons, which are optionally substituted with one or more functional groups. As will be appreciated by one of ordinary skill in the art, "aliphatic" is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties.* Thus, as used herein, the term "alkyl" includes straight, branched and cyclic alkyl groups. An analogous convention applies to other generic terms such as "alkenyl", "alkynyl" and the like. Furthermore, as used herein, the terms "alkyl", "alkenyl", "alkynyl" and the like encompass both substituted and unsubstituted groups. In certain embodiments, as used herein, "lower alkyl" is used to indicate those alkyl groups (cyclic, acyclic, substituted, unsubstituted, branched or unbranched) having 1-6 carbon atoms.
[0058] In certain embodiments, the alkyl, alkenyl and alkynyl groups employed in the invention contain 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-4 carbon atoms. Illustrative aliphatic groups thus include, but are not limited to, for example, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, -CH2-cyclopropyl, allyl, n-butyk sec-butyl, isobutyl, tert-butyl, cyclobutyl, -CH2-cyclobutyl, n-pentyl, sec-pentyl, isopentyl, tert-penryl, cyclopentyl, -CH2-cyclopentyl-n, hexyl, sec-hexyl, cyclohexyl, -CH2-cyclohexyl moieties and the like, which again, may bear one or more substituents. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, l-methyl-2-buten-l-yl, and the like. Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl and the like. [0059] The term "alkoxy" (or "alkyloxy"), or "thioalkyl" as used herein refers to an alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom or through a sulfur atom. In certain embodiments, the alkyl group contains 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl group contains 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl group contains 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl group contains 1-4 aliphatic carbon atoms. Examples of alkoxy, include but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert-butoxy, neopentoxy and n-hexoxy. Examples of thioalkyl include, but are not limited to, methylthio, ethylthio, propylthio, isopropylthio, n- butylthio, and the like.
[0060] The term "alkylamino" refers to a group having the structure -NHR'wherein R' is alkyl, as defined herein. The term "dialkylamino" refers to a group having the structure — N(R')2, wherein R' is alkyl, as defined herein. The term "aminoalkyl" refers to a group having the structure NH2R'-, wherein R' is alkyl, as defined herein. In certain embodiments, the alkyl group contains 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl group contains 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl group contains 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl group contains 1-4 aliphatic carbon atoms. Examples of alkylamino include, but are not limited to, methylamino, ethylamino, iso-propylamino and the like. [0061] Some examples of substituents of the above-described aliphatic (and other) moieties of compounds of the invention include, but are not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; -OH; -NO2; - CN; -CF3; -CH2CF3; -CHC12; -CH2OH; -CH2CH2OH; -CH2NH2; -CH2SO2CH3; -C(O)R ; - CO2(R); -CON(R')2; -OC(O)R ; -OCO2R ; -OCON(R)2; -N(R')2; -S(0)2R ; -N(R')S(O)2R , - S(O)2RN(R')2, -NR (CO)R wherein each occurrence of R independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl, wherein any of the aliphatic, heteroaliphatic, alkylaryl, or alkylheteroaryl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein. [0062] In general, the terms "aryl" and "heteroaryl", as used herein, refer to stable mono- or polycyclic, heterocyclic, polycyclic, and polyheterocyclic unsaturated moieties having preferably 3-14 carbon atoms, each of which may be substituted or unsubstituted. Substituents include, but are not limited to, any of the previously mentioned substitutents, i.e., the substituents recited for aliphatic moieties, or for other moieties as disclosed herein, resulting in the formation of a stable compound. In certain embodiments of the present invention, "aryl" refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl and the like. In certain embodiements of the present invention, the term "heteroaryl", as used herein, refers to a cyclic aromatic radical having from five to ten ring atoms of which one ring atom is selected from S, O and N; zero, one or two ring atoms are additional heteroatoms independently selected from S, O and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.
[0063] It will be appreciated that aryl and heteroaryl groups (including bicyclic aryl groups) can be unsubstituted or substituted, wherein substitution includes replacement of one or more of the hydrogen atoms thereon independently with any one or more of the following moieties including, but not limited to: aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; -OH; -NO2; -CN; -CF3; -CH2CF3; -CHC12; - CH2OH; -CH2CH2OH; -CH2NH2; -CH2SO CH3; -C(O)R ; -CO2(R); -CON(R)2; -OC(O)R ; - OCO2R ; -OCON(R)2; -N(R)2; -S(O)2R ; -N(R')S(O)2R , -S(0)2R'N(R')2, -NR'(C0)R wherein each occurrence of Rx independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl, wherein any of the aliphatic, heteroaliphatic, alkylaryl, or alkylheteroaryl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additionally, it will be appreciated, that any two adjacent groups taken together may represent a 4, 5, 6, or 7-membered cyclic, substituted or unsubstituted aliphatic or heteroaliphatic moiety. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein. [0064] The term "cycloalkyl", as used herein, refers specifically to groups having three to seven, preferably three to ten carbon atoms. Suitable cycloalkyls include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like, which, as in the case of other aliphatic, heteroaliphatic or hetercyclic moieties, may optionally be substituted with substituents including, but not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; -OH; -NO2; -CN; -CF3; -CH2CF3; -CHC12; - CH2OH; -CH2CH2OH; -CH2NH2; -CH2SO2CH3; -C(0)R ; -CO2(R); -CON(R)2; -OC(O)R ; - OCO2R ; -OCON(R')2; -N(R')2; -S(O)2R ; -N(R')S(O)2R , -S(0)2R'N(R')2, -NR'(C0)R' wherein each occurrence of R independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl, wherein any of the aliphatic, heteroaliphatic, alkylaryl, or alkylheteroaryl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additionally, it will be appreciated that any of the cycloaliphatic or heterocycloaliphatic moieties described above and herein may comprise an aryl or heteroaryl moiety fused thereto. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein. [0065] The term "heteroaliphatic", as used herein, refers to aliphatic moieties which contain one or more oxygen sulfur, nitrogen, phosphorus or silicon atoms, e.g., in place of carbon atoms. Heteroaliphatic moieties may be branched, unbranched, cyclic or acyclic and include saturated and unsaturated heterocycles such as morpholino, pyrrolidinyl, etc. In certain embodiments, heteroaliphatic moieties are substituted by independent replacement of one or more of the hydrogen atoms thereon with one or more moieties including, but not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; -OH; -NO2; -CN; -CF3; -CH2CF3; -CHC12; -CH2OH; -CH2CH2OH; -CH2NH2; - CH2SO2CH3; -C(O)R ; -C02(R ); -CON(R)2; -OC(O)R ; -OCO R ; -OCON(R)2; -N(R)2; - S(O)2R ; -N(R')S(O)2R', -S(O)2RN(R')2, -NR'(C0)R wherein each occurrence of R independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl, wherein any of the aliphatic, heteroaliphatic, alkylaryl, or alkylheteroaryl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additionally, it will be appreciated that any of the cycloaliphatic or heterocycloaliphatic moieties described above and herein may comprise an aryl or heteroaryl moiety fused thereto. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein.
[0066] The terms "halo" and "halogen" as used herein refer to an atom selected from fluorine, chlorine, bromine and iodine.
[0067] The term "haloalkyl" denotes an alkyl group, as defined above, having one, two, or three halogen atoms attached thereto and is exemplified by such groups as chloromethyl, bromoethyl, trifluoromethyl, and the like.
[0068] The term "heterocycloalkyl" or "heterocycle", as used herein, refers to a non- aromatic 5-, 6- or 7- membered ring or a polycyclic group, including, but not limited to a bi- or tr-cyclic group comprising fused six-membered rings having between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein (i) each 5- membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (ii) the nitrogen and sulfur heteroatoms may be optionally be oxidized, (iii) the nitrogen heteroatom may optionally be quatemized, and (iv) any of the above heterocyclic rings may be fused to a substituted or unsubstituted aryl or heteroaryl ring. Representative heterocycles include, but are not limited to, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl. In certain embodiments, a "substituted heterocycloalkyl or heterocycle" group is utilized and as used herein, refers to a heterocycloalkyl or heterocycle group, as defined above, substituted by the independent replacement of one or more of the hydrogen atoms thereon with but are not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; - OH; -N02; -CN; -CF3; -CH2CF3; -CHC12; -CH2OH; -CH2CH2OH; -CH2NH2; -CH2SO2CH3; - C(O)R ; -CO2(R); -CON(R)2; -OC(O)R ; -OC02R ; -OCON(R)2; -N(R)2; -S(O)2R ; - N(R')S(O)2R, -S(O)2RN(R')2, -N R (CO) R wherein each occurrence of R independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl, wherein any of the aliphatic, heteroaliphatic, alkylaryl, or alkylheteroaryl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substitutents described above and herein may be substituted or unsubstituted. Additional examples or generally applicable substituents are illustrated by the specific embodiments shown in the Examples which are described herein.
[0069] The term "ligand candidate" refers to a compound that possesses or has been modified to possess a reactive group that is capable of forming a covalent bond with a complimentary or compatible reactive group on a target. The reactive group on either the ligand candidate or the target can be masked with, for example, a protecting group. [0070] The phrase "site of interest" refers to any site on a target on which a ligand can bind. As used herein, a site of interest is any site that is outside of the primary binding site of a protein. For example, if a target is an enzyme, a site of interest is a site that is not the active site. If a target is a receptor, a site of interest is a site that is not the binding site of the receptor's ligand. '
[0071] The terms "target," "Target Molecule," and "TM" are used interchangeably and in the broadest sense, and refer to a chemical or biological entity for which the binding of a ligand has an effect on the function of the target. The target can be a molecule, a portion of a molecule, or an aggregate of molecules. The binding of a ligand may be reversible or irreversible. Specific examples of target molecules include polypeptides or proteins (e.g., enzymes, including proteases, e.g. cysteine, serine, and aspartyl proteases), receptors, transcription factors, ligands for receptors, growth factors, cytokines, immunoglobulins, nuclear proteins, signal transduction components (e.g., kinases, phosphatases), allosteric enzyme regulators, and the like, polynucleotides, peptides, carbohydrates, glycoproteins, glycolipids, and other macromolecules, such as nucleic acid-protein complexes, chromatin or ribosomes, lipid bilayer-containing structures, such as membranes, or structures derived from membranes, such as vesicles. The definition specifically includes Target Biological Molecules ("TBMs") as defined below.
[0072] A "Target Biological Molecule" or "TBM" as used herein refers to a single biological molecule or a plurality of biological molecules capable of forming a biologically relevant complex with one another for which a small molecule agonist or antagonist has an effect on the ruction of the TBM. In a preferred embodiment, the TBM is a protein or a portion thereof or that comprises two or more amino acids, and which possesses or is capable of being modified to possess a reactive group that is capable of forming a covalent bond with a compound having a complementary reactive group. Illustrative examples of TBMs include: enzymes, receptors, transcription factors, ligands for receptors, growth factors, immunoglobulins, nuclear proteins, signal transduction components, glycoproteins, glycolipids, and other macromolecules, such as nucleic acid-protein complexes, chromatin or ribosomes, lipid bilayer-containing structures, such as membranes, or structures derived from membranes, such as vesicles. The target can be obtained in a variety of ways, including isolation and purification from natural source, chemical synthesis, recombinant production and any combination of these and similar methods.
[0073] Preferred protein targets include: cell surface and soluble receptor proteins, such as lymphocyte cell surface receptors; enzymes; proteases (e.g., aspartyl, cysteine, metallo, and serine); steroid receptors; nuclear proteins; allosteric enzymes; clotting factors; kinases (serine/threonine kinases and tyrosine kinases); phosphatases (serine/threonine, tyrosine, and dual specificity phosphatases, especially PTP-1B, TC-PTP and LAR); thymidylate synthase; bacterial enzymes, fungal enzymes and viral enzymes (especially those associated with HIV, influenza, rhinovirus and RSV); signal transduction molecules; transcription factors; proteins or enzymes associated with DNA and/or RNA synthesis or degradation; immunoglobulins; hormones; and receptors for various cytokines. Illustrative examples of receptors include for example, erythropoietin (EPO), granulocyte colony stimulating (G-CSF) receptor, granulocyte macrophage colony stimulating (GM-CSF) receptor, thrombopoietin (TPO), interleukins, e.g. IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-11, IL-12, growth hormone, prolactin, human placental lactogen (LPL), CNTF, oncostatin, RANTES, MlPb, IL-8, insulin, insulinlike growth factor 1 (IGF-1), epidermal growth factor (EGF), heregulin-a and heregulin-b, vascular endothelial growth factor (VEGF), placental growth factor (PLGF), tissue growth factors (TGF-α and TGF-β), and nerve growth factor (NGF). Other targets include various neurotrophins and their ligands, other hormones and receptors such as, bone morphogenic factors, follicle stimulating hormone (FSH), and luteinizing hormone (LH), CD40 ligand, apoptosis factor-1 and -2 (AP-1 and AP-2), p53, bax/bcl2, mdm2, caspases (1, 3, 8 and 9), cathepsins, IL-1 /IL-1 receptor, BACE, HIV integrase, PDE IV, Hepatitis C helicase, Hepatitis C protease, rhinovirus protease, tryptase, cPLA (cytosolic Phospholipase A2), CDK4, c-jun kinase, adaptors such as Grb2, GSK-3, AKT, MEKK-1, PAK-1, raf, TRAF's 1- 6, Tie2, ErbB 1 and 2, FGF, PDGF, PARP, CD2, C5a receptor, CD4, CD26, CD3, TGF- alpha, NF-kB, IKK beta, STAT 6, Neurokinnin-1, CD45, Cdc25A, SHIP-2, human p53, bax/bcl2, IgE/IgER, ZAP-70, lck, syk, ITK/BTK, TACE, Cathepsin S, K and F, CDlla, LFA/ΪCAM, VLA-4, CD28/B7, CTLA4, TNF alpha and beta, (and the p55 and p75 TNF receptors), CD40L, p38 map kinase, IL-2, IL-4, 11-13, IL-15, Rac 2, PKC theta, IL-8, TAK-1, jnk, IKK2 and IL-18.
[0074] 3) Synthesis of Inventive Compounds and Libraries of Compounds: [0075] As described in more detail in the Exemplification herein, a variety of tethering reagents and libraries of reagents (which compounds and libraries are described in detail above) can be prepared. In general, these tethering reagents and libraries of reagents are prepared by derivatizing desired building blocks with a suitable linker. It will be appreciated that a variety of building blocks can be utilized for the tethering reagents and libraries of reagents. For example, alkyl acids, aryl acids, primary alkyl amines, secondary alkyl amines, secondary aryl amines, aldehydes and ketones can be utilized as described in more detail above and herein. It will be appreciated that each of these building blocks may be purchased from a commercial source, or may be synthesized to generate a building block of particular interest. In addition, building blocks that are purchased from a commercial source may also be further derivatized to generate additional diverstiy (see "1+ nub" chemistry, and the synthesis of "N-side" and "C-side" compounds and libraries as described in the exemplification herein).
[0076] Certain exemplary linkers for use in the invention (the synthesis of which are described in the exemplification herein) include, but are not limited to the following linkers shown directly below:
Figure imgf000030_0001
[0077] It will be appreciated that the amine linkers are generally employed for building blocks bearing a carboxylate, sulfonylchloride or isocyanate, while carboxylate linkers are generally employed for the derivatization of amines. It will also be appreciated that the length of the linker can be varied as necessary to sample the surface of a given protein, or more generally, of a target of interest. In general, standard coupling conditions are utilized to couple a desired building block and a desired linker as described in more detail herein. It will also be appreciated that once desired building blocks are attached to appropriate linkers, these building blocks can be further derivatized to "customize" reagents, as described in more detail herein.
[0078] 3) Uses [0079] As described above, the present invention provides novel compounds and libraries of compounds that are useful in the development of novel drug leads using the tethering method.
[0080] The general tethering method relies upon the formation of a covalent bond between the target and a potential ligand. The covalent bond that is formed between the target and the potential ligand allows the facile determination of both binding stoichiometry and binding location. The tethering method is described in U.S. Patent No. 6,335,155, PCT Publication No. WO 00/00823, and Erlanson et al, Proc. Nat. Acad. Sci. USA 97:9367-9372 (2000) which are all incorporated herein by reference and is described briefly below. In general, the compounds and libraries of compounds are useful in the above-described method. Thus, in another embodiment of the invention, a method for ligand discovery is provided comprising: 1) contacting a target that comprises a chemically reactive group at or near a site of interest with a compound or library of compounds as described herein, which compound or library of compounds is capable of forming a covalent bond with a chemically reactive group; 2) forming a covalent bond between the target and the compound thereby forming a target-compound conjugate; and 3) identifying the target compound conjugate. [0081] Figure 1 schematically illustrates one embodiment of the tethering method. In this case, the target is a protein and the covalent bond is a disulfide bond. As shown, a thiol- containing protein is reacted with a plurality of ligand candidates. Ligand candidates are potential ligands that have been modified to include a moiety that is capable of forming a disulfide bond. This moiety can be a thiol group or a masked thiol such as a disulfide of the formula -SSR where R is unsubstituted Ci-Cio aliphatic, substituted - o aliphatic, unsubstituted aryl or substituted aryl. In certain embodiments, R is selected to enhance the solubility of the potential ligand candidates. Illustrative examples of ligand candidates include those as described in detail above and herein. In certain exemplary embodiments, ligand candidates include, but are not limited to:
Figure imgf000032_0001
wherein r is 1 or 2; and t is 0, 1 or 2.
[0082] It will also be appreciated that once a ligand candidate is identified using the tethering method described above, tethered compounds as described above may be characterized using X-ray crystallography methods. When using X-ray crystallography as a characterization method (or other characterization methods), it is desirable to obtain homogeneous compounds after exposure to reducing conditions. Thus, in certain embodiments, compounds and libraries of special interest include those compounds and
libraries wherein Wn represents one of the structures having a substituted thiosulfonate moiety, which moiety, upon exposure to reducing conditions, results in homogeneous compounds:
Figure imgf000033_0001
wherein r is 1 or 2; and R^2 is an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, (alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety.
[0083] In certain embodiments of special interest R^ is methyl or phenyl.
[0084] As shown, a ligand candidate that possesses an inherent binding affinity for the target is identified and a corresponding ligand that does not include the disulfide moiety is made comprising the identified binding determinant (represented by the circle). [0085] Figure IB schematically illustrates the theory behind tethering. When a thiol- containing protein is equilibrated with at least one disulfide-containing ligand candidate, equilibrium is established between the modified and unmodified protein. In preferred embodiments, the reaction occurs in the presence of a reducing agent. If the ligand candidate does not have an inherent binding affinity for the target protein, the equilibrium is shifted toward the unmodified protein. In contrast, if the ligand candidate does have an inherent affinity for the protein, equilibrium shifts toward the modified protein. Both situations are illustrated in Figure IB. In the first, the RA moiety of the ligand candidate possesses little or no binding affinity for the protein. Thus, the formation of the protein-ligand conjugate is a function of the probability of forming a disulfide bond given the concentration of the protein, the ligand candidate, and reducing agent. In the second, the RB moiety of the ligand candidate possesses an inherent binding affinity for the protein. Consequently, once the disulfide bond is formed between the protein and the ligand candidate, the protein-ligand conjugate is stabilized. Thus, equilibrium is shifted toward the formation of the protein- ligand conjugate.
[0086] To further illustrate tethering, the method has been applied to thymidylate synthase ("TS"), an essential enzyme for virtually all living organisms. TS, along with dihydrofolate reductase ("DHFR") and serine hydroxymethylase, forms a biochemical functional unit, the thymidylate synthase cycle, that provides the sole de novo pathway for synthesis of the DNA base thymidine 5'-monophosphate ("dTMP") from the RNA base dUMP. Both TS and DHRF are targets for anticancer drug development. Because the TS gene is also found in many viruses, it is also a target for development of anti-parasitic, anti- fungal, and anti-viral agents.
[0087] TS is an ideal validating target for several reasons. First, numerous high resolution crystal structures of various TS enzymes have been determined so that structural information can be incorporated into compound design. Second, a simple colorimetric assay exists for determining whether a potential ligand binds to TS. This assay depends on the rate of conversion of 5,10-CH^HUfolate to H2folate in the presence of dUMP. A second assay for binding is also spectrophotometric and relies on competition with pyridoxal-5 '-phosphate ("PLP"), which forms a complex with TS with a unique spectral signature. [0088] The TS chosen for the purposes of illustration is the E. coli TS. Like all TS enzymes, it contains a naturally occurring cysteine residue in the active site (Cys 146) that can be used for tethering. The E. coli TS includes four other cysteines but these are not conserved among other TS enzymes and are buried and thus not accessible. However, if one or more of these cysteines were reactive toward disulfides, then mutant versions of these enzymes can be used where these cysteines are mutated to another amino acid such as alanine.
[0089] In the first experiment, wildtype TS and the C146S mutant (wherein the cysteine at position 146 has been mutated to serine) were contacted with cystamine, H2NCH2CH2SSCH2CH2NH2. The wildtype TS enzyme reacted cleanly with one equivalent of cystamine while the mutant TS did not react indicating that the cystamine was reacting with and was selective for Cys- 146.
[0090] The wildtype TS was subjected to several tethering experiments with different pools of ligand candidates. Figure 2 illustrates two representative tethering experiments wherein the ligand candidates were of the formula
Figure imgf000034_0001
[0091] This is a specific embodiment of the genus of ligand candidates of the formula RSSR where R corresponds to RcC(=O)NHCH2CH2- and R corresponds to -CH2CH2NH2. Rc is unsubstituted -Cio alkyl, substituted C C^ alkyl, unsubstituted aryl, or substituted aryl, and is the variable moiety among this pool of library members.
[0092] Figure 2A is the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates with little or no binding affinity for TS. In the absence of any binding interactions, the equilibrium in the disulfide exchange reaction between TS and an individual ligand candidate is to the unmodified enzyme. This is schematically illustrated by the following equation.
Figure imgf000035_0001
[0093] As expected, the peak that corresponds to the unmodified enzyme is one of two most prominent peaks in the spectrum. The other prominent peak is TS where the thiol of Cys 146 has been modified with cysteamine. Although this species is not formed to a significant extent for any individual library member, the peak is due to the cumulative effect of the equilibrium reactions for each member of the library pool. When the reaction is run in the presence of a thiol-containing reducing agent such as 2-mercaptoethanol, the active site cysteine can also be modified with the reducing agent. Because cysteamine and 2- mercaptoethanol have similar molecular weights, their respective disulfide bonded TS enzymes are not distinguishable under the conditions used in this experiment. The small peaks on the right correspond to discreet library members. Notably, none of these peaks are very prominent. Figure 2A is characteristic of a spectrum where none of the ligand candidates possesses an inherent binding affinity for the target.
[0094] Figure 2B is the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates where one of the ligand candidates possesses an inherent binding affinity to the enzyme. As can be seen, the most prominent peak is the one that corresponds to TS where the thiol of Cys 146 has been modified with the N-tosyl-£)-proline compound. This peak dwarfs all others including those corresponding to the unmodified enzyme and TS where the thiol of Cysl46 has been modified with cysteamine. Figure 2B is an example of a mass spectrum where tethering has captured a moiety that possesses a strong inherent binding affinity for the desired site.
[0095] When tethering occurs in the presence of a reducing agent, the process becomes more thermodynamically driven and equilibrium-controlled. Figure 3 is an illustration of this phenomenon and shows three experiments where TS is reacted with the same library pool containing the selected N-tosyl-D-proline compound in the presence of increasing concentration of the reducing agent, 2-mercaptoethanol.
[0096] Figure 3A is the deconvoluted mass spectrum when the reaction is performed without 2-mercaptoethanol. The most prominent peak corresponds to TS that has been modified with cysteamine. However, the peak corresponding to N-tosyl-Z)-proline is nevertheless moderately selected over the other ligand candidates. Figure 3B is the deconvoluted mass spectrum when the reaction is in the presence of 0.2 mM 2- mercaptoethanol. In contrast, to the spectrum in Figure 3A, the peak corresponding to N- tosyl-D-proline is the most prominent peak and thus is strongly selected over the other ligand candidates. Finally, Figure 3C is the deconvoluted mass spectrum when the reaction is in the presence of 20 mM 2-mercaptoethanol. Not surprisingly, the most prominent peak under such strongly reducing conditions is the unmodified enzyme. Nevertheless, the peak corresponding to N-tosyl-E>-proline is still selected over that of the other ligand candidates in the library pool.
[0097] Figure 3 highlights the fact that the degree of cysteine modification in a target protein by a particular ligand candidate that possesses an inherent affinity for the target is, in part, a function of the reducing agent concentration. In general, the higher the binding affinity of the ligand candidate for the target protein, the higher the concentration of reducing agent that can be used and still get strong selection. As a result, the concentration of the reducing agent used in the tethering screen can be used as a surrogate for binding affinity as well as to set a lower limit of binding affinity the ligand candidate must have to be strongly selected.
[0098] As stated previously, the tethering method can be used with a single ligand candidate or a plurality of ligand candidates. In preferred embodiments, the tethering method is used to screen a plurality of ligand candidates (e.g., 5, 20, 100, 500, 1000, and even >1000) to maximize throughput and efficiency.
[0099] A structure-activity relationship ("SAR") can be developed using information from a tethering experiment in much the same way SAR is developed using traditional assays. For example, ligand candidates with Rcs on the left hand side of the scheme below were strongly selected against the E. coli TS but those ligand candidates with Rcs on the right hand side were not.
Figure imgf000037_0001
[00100] Based on the data from screening approximately 1200 compounds, it was determined that the phenyl-sulfonamide core and the proline ring are essential. For example, although TS appears to accommodate a great deal of flexibility around the phenyl ring where the phenyl ring can be unsubstituted or substituted with a range of groups including methyl, t- butyl, and halogen, its presence is required for selection. Similarly, the proline ring appears essential because compounds where it was replaced with phenylalanine, phenylglycine or pyrrole were not selected.
[00101] In addition to the above, further experiments were performed to validate that the compounds selected from tethering correspond to those with binding affinity for the target. In one illustrative example, the tethering experiment is performed in the presence of a known substrate. If the selected ligand candidate possesses an inherent binding affinity for the target, it would be resistant to displacement by the substrate. In contrast, a ligand candidate that lacks an inherent binding affinity or cysteamine would be easily displaced by the substrate. Another illustrative example is traditional enzymatic assays on the tether-free analog. For example, the affinity of the Rc portion of the ligand fragment was determined using Michaelis-Mention kinetics. The Kj of the free acid 1 was 1.1 ± 0.25 mM. Notably, the free acid competed with the natural substrate dUMP. Thus, N-tosyl-jD-proline 1 is a weak but competitive inhibitor of TS
Figure imgf000038_0001
[00102] In another embodime , the naturally occurring cysteine residue in the active site was mutated to a serine (C146S) and another cysteine was introduced (L143C or H147C). Tethering using the C146S/L143C mutant produced similar results as the wild type enzyme. Notably, the N-tosyl-D-proline analog was strongly selected. In contrast, the C146S/H147C did not select the N-tosyl-Z -proline analog but several other molecules were selected. These < results are believed to reflect the differences in the local binding environment surrounding the reactive cysteine and the geometric constraints of the disulfide linker. [00103] X-ray crystallography was used to solve the three-dimensional structures of the native enzyme and several complexes to confirm that the information obtained from tethering can be correlated with productive binding to the target. Table 1 details crystallographic data and refinement parameters. One complex was of the free acid of Ν-tosyl-D-proline bound to TS (fourth entry in Table 1). Another complex was of the Ν-tosyl-D-proline derivative tethered to the active site cysteine (Cys-146) (second entry in Table 1). Yet another complex was of Ν-tosyl-D-proine derivative tethered to the C146S/L143C mutant (third entry in Table
1).
TABLE 1 rms rms
Reflections deviation deviation
Cell <n°) bond bond
Space dimensions. Resolution, Completeness.* flIym fiαyn,* Rfr..,' lengths, angles.
Data set group* A A Overall Unique % (0,* % l/σ % % A deg
Native 12^ a = 131.17 10 - 1.75 104,019 36,586 96.7(91.6) 4.9 (33.8) 20.5 (4.0) 19.8 24.4 0.010 2.30
C146 tethered P63 a - 126.22 c = 67.02 10- 2.00 97,445 41,001 98.8 (94.5) 4.4 (26.0) 14.7 (4.1) 19.8 26.8 0.010 2.59
N-tosyl-D-proline
L143C tethered P63 a = 126.33 c = 67.12 10 - 2.15 78,793 32,045 96.7(92.1) 8.1 (28.6) 12.8(4.5) 19.6 26.7 0.014 3.06
N-tosyl-o-proline
Noncovalent I2ι3 a = 131.88 10 - 1.90 202,300 31,422 100 (100) 7.4 (28.2) 19.7 (3.8) 19.2 23.8 0.011 2.49
N-tosyl-o-proline
Glu-TP P63 a = 126.14 c - 66.81 10 - 2.00 143,599 40,497 99.4(96.9) 8.5 (31.9) 13.9(4.0) 19.4 25.1 0.007 2.15
Glu-TP-ff-Ala P63 a - 126.03 c = 66.84 10 - 1.75 142,016 58,487 95.8 (85.2) 4.0 (22.5) 17.1 (4.9) 18.0 21.4 0.007 2.00
This is not a "true" free R factor because the starting model was a fully refined structure. However, the free R factor set of reflections was kept constant for each of the above refinements.
"The I2t3 crystal contains one monomer per asymmetric unit. The P63 f orm contains the biologically relevant homodimer. /alues in parentheses are for the highest resolution bin. '"ι» (0 - ∑wi|'hki(/hki>|/∑ u( ki, where Jt*i is the Intensity of reflection hw.
'fiάwt - ∑hkilifobj - IFukll/lf bJ. where fa* and fat are the observed and calculated structure factors, respectively, or the data used in refinement. 'RfrM - ΣhkillFobsl - iFukll/lFotal. where Foi» and 5Λ are the observed and calculated structure factors, respectively, for 10% of the data omitted from refinement
[00104] Significantly, the location of the N-tosyl-D-proline moiety is very similar in all three cases (RMSD of 0.55 - 1.88 A, compared to 0.11 - 0.56 A for all Cα carbons in the protein). The fact that the N-tosyl-D-proline substituents closely overlap while the alkyl- disulfide tethers converge onto this moiety from different cysteine residues supports the notion that the N-tosyl-D-proline moiety, not the tether, is the binding determinant. [00105] As can be seen, tethering is a powerful method that can identify ligands that bind to a site of interest in a target. Tethering can be used alone or in combination with other medicinal chemistry methods to identify and optimize a drug candidate. [00106] In one aspect of the present invention, tethering is used to identify a binding determinant (e.g. Rc) and then traditional medicinal chemistry is used to make higher affinity compounds containing the identified binding determinants or variations thereof. In one embodiment, tethering is used to both identify a binding determinant and also used to assess whether compounds containing variations of the identified binding determinants bind to the target with higher affinity. In other words, tethering can be used as an alternative to traditional binding experiments where either functional assays are not available or are susceptible to artifacts. This approach is schematically illustrated in Figure 4. As can be seen, tethering is used to identify a binding determinant RD. Once such a binding determinant is identified, traditional medicinal chemistry approaches are used to synthesize variants of RD in a modified library. The modified library of ligand candidates would include variants of RD such as isosteres and homologs thereof. The modified library can also include "extended" compounds that include RD or variations thereof as well as other binding determinants that can take advantage of adjacent binding regions. Figure 4 illustrates a selected compound from the modified library wherein the original binding determinant R was modified to R and the selected compound includes a second binding determinant RL. [00107] An illustration of the approach outlined in Figure 4 is as follows where derivatives of the selected N-tosyl-D-proline compound were made and tested as a series of ligand candidates using tethering. Based on the crystal structure of N-tosyl-D-proline bound to TS, the methyl group off the phenyl ring was in a promising location for use as a derivitization point. Eighty eight derivatives having six different linker lenths were synthesized and the inhibition constants of the untethered versions of the selected ligand candidates were determined. Two of the best compounds were:
Figure imgf000039_0001
[00108] The Kj of compound 2 was determined to be about 55 μM and the Kj of compound
3 was determined to be about 40 μM.
[00109] In another aspect of the present invention, methods are provided for identifying two binding determinants that are subsequently linked together. In general, the method comprises: a) identifying a first compound that binds to a target protein; b) identifying a second compound that binds to the target protein; and, c) linking the first compound and second compound through a linker element to form a conjugate molecule that binds to the target protein. In preferred embodiments, the conjugate molecule binds to the target protein with higher binding affinity than either the first compound or second compound alone.
[00110] In one embodiment, the first compound is of the formula RKSSR and the second compound is of the formula R SSR (where R" is as previously described and Rκ and RL are each independently Cι-C20 unsubstituted aliphatic, -C2o substituted aliphatic, unsubstituted aryl, or substituted aryl) and the first and second compounds bind to the target protein through a disulfide bond. Figure 5 is a schematic illustration of this method where two separate tethering experiments are used to identify binding determinants Rκ and RL that are subsequently linked together to form a conjugate molecule that binds to the target protein. In another embodiment, the tethering experiments to identify binding determinants Rκ and RL occur simultaneously. In this way, it is assured that the two identified binding determinants bind to the target protein at non-overlapping sites.
[00111] In another embodiment, the first compound is identified using tethering and the second compound is identified through a non-tethering method. In one embodiment, the non- tethering method comprised rational drug design and traditional medicinal chemistry. The crystal structure of N-tosyl-D-proline bound to TS revealed that the tosyl group is in roughly the same position and orientation as the benzamide moiety of methylenetetrahydrofolate, the natural cofactor for the TS enzyme. Consequently, the glutamate moiety of methylenetetrahydrofoloate was grafted onto compound 1. Table 2 shows a selected number of these compounds. TABLE 2
COMPOUND
Figure imgf000041_0001
Figure imgf000041_0002
!2 \ζ^ -^s"cp2H 246 ± 4φ.M
[00112] There is a distinct preference for the D-enantiomer of proline (compound 5) over the -enantiomer (compound 4) and the α-carboxylate of the glutamate residue is important because removing it (compound 12) or changing it to a primary amide (compound 10) correlates with a significant loss in binding affinity.
[00113] In another aspect of the present invention, a variation on the tethering method is provided for use in making and optimizing compoundsThe method comprises: a) providing a target having a reactive nucleophile at or near a site of interest; and b) contacting the target with an extender thereby forming a target-extender complex wherein the extender comprises a first functionality that reacts with the nucleophile in the target to form a covalent bond and a second functionality that is capable of forming a disulfide bond; c) contacting the target-extender complex with a ligand candidate that is capable of forming a disulfide bond; d) forming a disulfide bond between the target-extender complex and the ligand candidate thereby forming a target-extender-ligand conjugate; and e) identifying the ligand candidate present in the target-extender-ligand conjugate. Optionally, the target is contacted with a ligand candidate in the presence of a reducing agent. [00114] Illustrative examples of suitable reducing agents include but are not limited to: cysteine, cysteamine, dithiothreitol, dithioerythritol, glutathione, 2-mercaptoethanol, 3- mercaptoproprionic acid, a phosphine such as tris-(2-carboxyethyl-phosphine) ("TCEP"), or sodium borohydride. In one embodiment, the reducing agent is 2-mercaptoethanol. In another embodiment, the reducing agent is cysteamine. In another embodiment, the reducing agent is glutathione. In another embodiment, the reducing agent is cysteine. [00115] In one embodiment, the target comprises a -SH as the reactive nucleophile and the extender comprises a first functionality that is capable of forming a covalent bond with the reactive nucleophile on the target and a second functionality that is capable of forming a disulfide bond. In another embodiment, the reactive nucleophile on the target is a naturally occurring -SH from a cysteine that is part of the naturally occurring protein sequence. In another embodiment, the reactive nucleophile on the target is an engineered -SH group where mutagenesis was used to mutate a naturally occurring amino acid to a cysteine. [00116] In one embodiment, the first and second functionalities of the extender are each independently a -SH or a masked -SH. An illustrative example of a masked thiol is a disulfide of the formula -SSR where R is as previously described. In this embodiment, the covalent bond formed between the target and the extender is a disulfide bond and thus is a reversible covalent bond. In one variation of the method, the target is contacted with the extender prior to contacting the target-extender complex with one or more ligand candidates. In another variation, the target is contacted with a pool comprising the extender and one or more ligand candidates.
[00117] In another embodiment, the first functionality is a group that is capable of forming an irreversible covalent bond with the reactive nucleophile of the target under conditions that do not denature the target and the second functionality is a -SH or a masked -SH. In one embodiment, the first functionality is a group capable of undergoing SN2-like addition. Illustrative example of such extenders include: (i) α-halo acids such as
Figure imgf000042_0001
(ii) fluorophosphonates such as
Figure imgf000043_0001
(iii) epoxides such as
Figure imgf000043_0002
(iv) aziridines such as
Figure imgf000043_0003
(v) thiiranes such as
Figure imgf000043_0004
(vi) halomethyl ketones/amides such as
Figure imgf000043_0005
where R is unsubstituted -C20 aliphatic, substituted Cι-C20 aliphatic, unsubstituted aryl, and substituted aryl; R' is H, -SR wherein R has been previously defined; and X is a leaving group. Illustrative examples of include halogen, N2, OR, -P(=O)Ar2, -NO(C=O)R, -(C=O)R, -SR and vinyl sulfones.
In another embodiment, the first functionality is a group capable of undergoing SN aryl like addition. Illustrative examples of suitable groups include 7-halo-2,l,3-benzoxadiazaoles, and ortho/para nitro substituted halobenzenes such as
Figure imgf000044_0001
where R' and X are as previously defined.
[00118] In another embodiment, the first functionality is a group capable of undergoing
Michael-type addition. Illustrative examples of suitable groups include any moiety that includes a double or triple bond adjacent to an electron withdrawing system such as a carbonyl, imines, quinines, CN, NO2, and -S(=O) -. Illustrative examples of such extenders include:
Figure imgf000044_0002
where R' is as previously defined.
[00119] Figure 6 illustrates one embodiment of the tethering method using extenders. As shown, a target that includes a reactive nucleophile -SH is contacted with an extender comprising a first functionality X that is capable of forming a covalent bond with the reactive nucleophile and a second functionality -SR (where R is the same as R as defined above) that is capable of forming a disulfide bond. A tether-extender complex is formed which is then contacted with a plurality of ligand candidates. The extender provides one binding determinant (circle) and the ligand candidate provides the second binding determinant (square) and the resulting binding determinants are linked together to form a conjugate compound.
[00120] To further illustrate the tethering method using extenders, the method has been applied to a anti-apoptotic target caspase-3, a member of the cysteine aspartyl protease family. There are currently about a dozen known members of the caspase family, many of which are involved in the initiation or propagation of the apoptotic cascade. Caspases are potential drug targets for a variety of therapeutic indications involving excessive or abnormal levels of programmed cell death such as stroke, traumatic brain injury, spinal cord injury, Alzheimer's disease, Huntington's disease, Parkinson's disease, cardiovascular diseases, liver failure, and sepsis. Moreover, caspase-3 includes a naturally occurring cysteine residue at the active site and has been well characterized both functionally and crystallographically. [00121] A suitable extender for use in the caspase-3 active site was designed using the fact that small aspartyl-based arylacyloxymethyl ketones are known to react irreversibly with the active site cysteine. Two illustrative examples of suitable extenders for use with caspase-3 or other thiol proteases include compounds 13 and 14.
Figure imgf000045_0001
13 14
[00122] As can be seen, compounds 13 and 14 include an aspartic acid moiety as the binding determinant. Notably, the carbonyl of the aspartic acid moiety is also part of the first functionality (the arylacyloxymethyl ketone moiety) that forms a covalent bond with the thiol of the active site cysteine. Extenders 13 and 14 also include a second functionality, a masked
-SH in the form of a thioester that can be unmasked at the appropriate time. For example, the thioester can be converted into the free thiol by treating the target-extender complex with hydroxylamine.
[00123] Both extenders were shown to selectively modified caspase-3 at the active site cysteine and were treated with hydroxylamine to generate the following target-extender complexes:
Figure imgf000045_0002
13» 14'
[00124] Target-extender complexes 13' and 14' were each used in the tethering method against a library of about 10,000 ligand candidates. An illustrative example of a selected ligand-candidate using target-extender complex 13' is
Figure imgf000045_0003
[00125] An illustrative example of a selected ligand candidate using target-extender complex 14' is
Figure imgf000046_0001
16
[00126] Notably, ligand candidate 15 was not selected by target-extender complex 14' and ligand candidate 16 was not selected by target-extender complex 13'. Structure-activity relationships among the selected compounds were also evident. For example, ligand candidate 17,
Figure imgf000046_0002
which is identical to ligand candidate 15 except that it lacks a hydroxyl group was not selected by either target-extender complexes 13' or 14'.
[00127] To assess how the extenders and the selected ligand candidates were binding to the target, two structures of the target-extender ligand conjugates were determined. The first structure was of the conjugate that is formed when target-extender complex 13' is contacted with ligand candidate 15. The second structure was of the conjugate that is formed when target-extender complex 14' is contacted with ligand candidate 16. Table 3 summarizes selected crystallographic data for these structures.
TABLE 3
Figure imgf000046_0003
[00128] Notably, the aspartic acid moiety of both extenders was superimposable with the aspartyl residue in a known tefrapeptide substrate. With respect to the binding determinant of ligand candidate 15, the salicylate sulfonamide makes numerous contacts with the protein including four hydrogen bonds. The salicylate moiety occupies the P4 pocket of the enzyme that preferentially recognizes aspartic acid in caspase-3. With respect to the binding determinant of ligand candidate 16, the sulfone makes some of the same contacts as the salicylate.
[00129] Given that the binding determinants from the extender and the ligand candidates were making productive contacts with the active site of caspase-3, compounds were designed where the disulfides were replaced with more stable linkages. In addition, derivatives were made to probe the SAR of the binding determinants. With respect to the conjugate comprising extender 13 and ligand candidate 15, the target-extender ligand conjugate comprises:
Figure imgf000047_0001
[00130] From this conjugate, a class of potent caspase-3 inhibitors was made comprising the moiety
Figure imgf000047_0002
[00131] Four illustrative examples of compounds that were made based on the conjugate both for optimization and for SAR are disclosed in Table 4.
TABLE 4
Compound K,(μM)
Figure imgf000048_0001
[00132] As can be seen, a conservative approach was taken wherein the two sulfur atoms were replaced with two methylene units and the arylacyloxymethylketone (first functionality) was replaced with a simple aldehyde resulting in compound 18, a potent inhibitor of caspase- 3 with a K; of 2.8 μM. Removing the hydroxyl group to yield compound 19 reduced the affinity by a factor of five, confirming the SAR observed in the tether screen. Removing both the hydroxyl group and the acid moiety to yield compound 20 ablated binding affinity entirely. Modeling studies suggested that replacing the methylene linker with a rigid aminobenzyl moiety would effectively bridge the distance between the aspartyl group and the salicylate while reducing the enfropic costs of the linker. Indeed, as can be seen, compound 21 has a Kj that is more than 10 fold better than compound 18.
[00133] Similarly, a novel class of caspase-3 inhibitors resulted from the target-extender ligand conjugate comprising extender 14 and ligand candidate 16,
Figure imgf000049_0001
[00134] In one embodiment, the compounds comprise the moiety
HO H2C f
[00135] In another embodiment, the compounds are of the structure:
Figure imgf000049_0002
where Y is CH2, S, SO, SO2, and R12 is unsubstituted aryl or substituted aryl. In another embodiment, R12 is a unsubstituted heteroaryl or substituted heteroaryl. An illustrative example of a compound of this class is compound 22 with a K; of 0.33 μM. [00136] The salicylate sulfonamide-containing compounds of the present invention are additionally noteworthy. The identification of salicylate sulfonamide as a suitable P4-binding fragment would not have occurred using traditional medicinal chemistry. Using compound 21 as an example, the salicylate sulfonamide-less version of compound 21 inhibits caspase-3 with a Kj of approximately 28 μM. The addition of the salicylate sulfonamide to this fragment improves binding about 200 fold and results in compound 21 that has a Kj of approximately 0.16 μM. In contrast, the binding affinity decreases if one uses a known tripeptide that binds to P1-P3 sites of caspase-3 such as compound I as the starting point.
Figure imgf000049_0003
[00137] As can be seen compound I has a Kj of 0.051 μM and the addition of the salicylate sulfonamide moiety to this compound yields compound II that shows about a 300 fold decrease in binding affinity. Because of this dramatic decrease, exploring P4 binding with fripeptides would not have resulted in the identification of salicylate sulfonimide as a suitable P4-binding fragment. Yet, compounds that have this fragment available for binding to P4 are potent inhibitors. Consequently, this example highlights the power of tethering to identify important fragments that may not be found using traditional methods. As shown in the case of caspase-3, these fragments can be linked together to form powerful antagonists or agonists of a target of interest.
[00138] Another illustration of the power of tethering is the use of tethering to identify and/or optimize small molecule modulators of 'protein-protein interactions such as those involving interleukin-2 ("IL-2"). Unlike well-defined binding pockets that are typically found in enzymes, protein-protein interactions occur over large amorphous surface areas and are generally intractable to high-throughput screening assays.
[00139] IL-2 is a cytokine with a predominant role in the proliferation of activated T helper lymphocytes. Mitogenic stimuli or interaction of the T cell receptor complex with antigen/MHC complexes on antigen presenting cells causes synthesis and secretion of IL-2 by the activated T cell, followed by clonal expansion of the antigen-specific cells. These effects are known as autocrine effects. In addition, IL-2 can have paracrine effects on the growth and activity of B cells and natural killer (NK) cells. These outcomes are initiated by interaction of IL-2 with its receptor on the T cell surface. Disruption of the IL-2/IL-2R interaction can suppress immune function, which has a number of clinical indications, including graft vs. host disease (GVHD), transplant rejection, and autoimmune disorders such as psoriasis, uveitis, rheumatoid arthritis, and multiple sclerosis. [00140] Various methods were used to discover a 3 μM (IC50) lead compound 23,
Figure imgf000050_0001
that inhibits the IL-2/TL-2Rα interaction. Traditional methods for further optimization were unsuccessful. Consequently, tethering was used. An x-ray structure of IL-2 bound to a derivative of compound 23 revealed a potential hydrophobic pocket that may provide additional affinity and tethering experiments were performed using two cysteine mutants of IL-2, Y31C and L72C, that were made to explore this site. [00141] These tethering experiments identified several fragments that bind to the adjacent hydrophobic pocket including those below:
Figure imgf000051_0001
The identified binding determinants were then merged onto compound 23 resulting in compounds with improved binding affinities. The best compound was compound 24 whose structure is shown below
Figure imgf000051_0002
that inhibited theIL-2/lL2Rα interaction with an IC50 of 65 nM, an over 45 fold improvement over compound 23. This example highlights how tethering can be used to identify/optimize compounds against targets that were traditionally intractable to high throughput screening. [00142] As can be seen in Figure 2, the compound bound to the target can be readily detected and identified by mass spectroscopy ("MS"). MS detects molecules based on mass- to-charge ratio (m/z) and can resolve molecules based on their sizes (reviewed in Yates, Trends Genet. 16: 5-8 [2000]). The target-compound conjugate can be detected directly in the MS or the target compound conjugate can be fragmented prior to detection. Alternatively, the compound can be liberated within the mass specfrophotometer and subsequently identified. Moreover, MS can be used alone or in combination with other means for detection or identifying the compounds covalently bound to the target. Further descriptions of mass spectroscopy techniques include Fitzgerald and Siuzdak, Chemistry & Biology 3: 707-715 [1996]; Chu et al, J. Am. Chem. Soc. 118: 7827-7835 [1996]; Siudzak, Proc. Natl. Acad. Sci. USA 91: 11290-11297 [1994]; Burlingame et al., Anal. Chem. 68: 599R-651R [1996]; Wu et al, Chemistry & Biology 4: 653-657 [1997]; and Loo et al, Am. Reports Med. Chem. 31: 319-325 [1996]). [00143] Alternatively, the target-compound conjugate can be identified using other means. For example, one can employ various chromatographic techniques such as liquid chromatography, thin layer chromatography and the like for separation of the components of the reaction mixture so as to enhance the ability to identify the covalently bound molecule. Such chromatographic techniques can be employed in combination with mass spectroscopy or separate from mass spectroscopy. One can also couple a labeled probe (fluorescently, radioactively, or otherwise) to the liberated compound so as to facilitate its identification using any of the above techniques. In yet another embodiment, the formation of the new bonds liberates a labeled probe, which can then be monitored. A simple functional assay, such as an ELISA or enzymatic assay can also be used to detect binding when binding occurs in an area essential for what the assay measures. Other techniques that may find use for identifying the organic compound bound to the target molecule include, for example, nuclear magnetic resonance (NMR), surface plasmon resonance (e.g., BIACORE), capillary electrophoresis, X-ray crystallography, and the like, all of which will be well known to those skilled in the art.
[00144] The methods described herein provide powerful techniques for generating drug leads, and allowing the identification of one or more fragments that bind weakly, or with moderate binding affinity, to a target at sites near one another, and the synthesis of diaphores or larger molecules comprising the identified fragments (monophores) covalently linked to each other to produce higher affinity compounds. The monophores, diaphores or similar multimeric compounds including further ligand compounds, are valuable tools in rational drug design, which can be further modified and optimized using medicinal chemistry approaches and structure-aided design.
[00145] Clearly, the monophores or multiphores identified in accordance with the present invention and the modified drug leads and drugs designed therefrom can be used, for example, to regulate a variety of in vitro and in vivo biological processes which require or depend on the site-specific interaction of two molecules. Molecules which bind to a polynucleotide can be used, for example, to inhibit or prevent gene activation by blocking the access of a factor needed for activation to the target gene, or repress transcription by stabilizing duplex DNA or interfering with the transcriptional machinery.
EQUIVALENTS [00146] The representative examples that follow are intended to help illustrate the invention, and are not intended to, nor should they be construed to, limit the scope of the invention. Indeed, various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including the examples which follow and the references to the scientific and patent literature cited herein. It should further be appreciated that the contents of those cited references are incorporated herein by reference to help illustrate the state of the art.
[00147] The following examples contain important additional information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and the equivalents thereof.
EXEMPLIFICATION [00148] The compounds of this invention and their preparation can be understood further by the examples that illustrate some of the processes by which these compounds are prepared or used. It will be appreciated, however, that these examples do not limit the invention. Variations of the invention, now known or further developed, are considered to fall within the scope of the present invention as described herein and as hereinafter claimed.
[00149] 1) General Description of Synthetic Strategy:
[00150] As described generally above, exemplary compounds and libraries of compounds are synthesized by coupling appropriate amine, carboxylic acid, sulfonyl chloride, etc. building blocks with appropriate linkers. Described in more detail below is the synthesis of exemplary linkers and exemplary compounds and libraries of compounds.
[00151] A. Synthesis of Exemplary Linkers:
[00152] 1. Amine linker
Figure imgf000053_0001
[00153] To cystamine dihydrochloride (lOOg, 444 mmol) was added 5 N NaOH (400 mL) and the suspension stirred until a clear solution formed. The solution was extracted with DCM (6 x 200 mL) and the combined DCM layers dried (Na2SO4), filtered and concentrated to afford 64.5 g of the desired free base (95 %). [00154] To a solution of the free base (422 mmol) in THF (285 mL) was added dropwise a solution of di-t-butyldicarbonate (0.5 eq, 212 mmol) in THF (212 mL). The reaction was allowed to stir overnight, then concentrated to an oil, taken up in 1 M NaHSO4 (500 mL), and washed with ethylacetate. The aqueous layer was cooled in an ice-bath, treated with 5 M NaOH (200 mL), and the resulting solution immediate washed with DCM. The DCM layers were combined, dried (Na2SO4), filtered and concentrated to afford 11.4 g of the desired mono-Boc cystamine (21 %). [00155] 2. Carboxylate linker
Figure imgf000054_0001
[00156] To tert-butyl N-(2-mercaptoethyl)carbamate (10 g, 56 mmol) in DMSO (20 mL) was added 3-mercaptopropionic acid (6 g, 57 mmol) and the solution heated at 70°C for 48 hours. The solution was cooled, and the resulting waxy solid dissolved in chloroform (200 mL) and washed with 5 % aqueous NaHC03 (4 x 50 mL). The aqueous layers were combined, carefully acidified to litmus with 1 N HCl, and washed with CHC13 (4 x 50 mL). The organic layers were combined, washed with brine, dried (Na2SO4), concentrated and then purified on silica gel (9/1 DCM/MeOH) to afford 1.8 g of a colorless oil (12 %).
[00157] 3. Synthesis of the alkoxyamine Linker:
Workυp: Trt-OH AcOH \ OH
BME *- /
BF3Et20 TrtS Recrystalization
50%
TrtOH
Figure imgf000054_0002
BF3Et20
[00158] Dissolve 1 eq. B-mercaptoethanol in AcOH. Add 1 eq. of trityl alcohol and heat until dissolved. Add 1 eq of BF3ET2O. After 10 min. quench the reaction with H O. Cone. in vacuo. Dilute into dichloromethane and wash 3x with 3N NaOH, with brine, and dry on sodium sulfate. Rotovap and recrystalize from EtOAc/Hexanes.
Figure imgf000055_0001
THF
o
Figure imgf000055_0002
[00159] Under N2 combine 2 eq. PPh3 and 2 eq. N-hydroxy phthalamide and dissolve in THF. Cool on ice/NaCl/isopropanol to -10°C. Add 2 eq. of diethyl azodicarboxylate via syringe over 1 min. Solution turns dark color. Wait 1 min. Add trityl protected B- mercaptoethanol as a solution in THF. React for 2 hours then let slowly warm to r.t. Remove solvent. Dissolve in minimum EtOAc. Remove ppt. via filtration. Remove solvent and chromatograph: Gradient to 7:1 then back down to 3:1 hex:etoac.
Figure imgf000055_0003
[00160] Dissolve phthalimide in THF. Add excess hydrazine (anhydrous, in THF). Ppt forms within 15 min. Let stir additional 30-40 min. Add 2x vol. 7:1 Hex:EtOAc. Filter through glass wool. R-Vap. Dissolve in min. etoac. Add 7:1 and filter again. Remove solvent and dry under vacuum.
Figure imgf000055_0004
FmocHN' sSTrt
FmocCI
Fmoc-CI
Extractive
Pyridine TrtS NHFmoc [00161] Dissolve alkoxyamine in THF under N2. Add 1.5 eq. of pyridine via syringe. Add solution of 9-Fluorenylmethyl chloroformate in THF. Rxn. ppt. during addition. Stir 20 min. Add ether (2x total volume of THF). Wash two times with 10% cifric acid. Wash once with brine. Dry on sodium sulfate, then remove solvent and dry under vacuum
.0. ^ _ ... Λ.
FmocHNT ^^ ^STrt TP, „:rn FmocH T ^^ ^SH
TFA/TES
TES \ A Isolated as
TFA HS v NHFmoc Crude
[00162] Dissolve trityl thiol in DCM. Add triethylsilane followed by TFA and monitor by TLC. When complete remove solvent and then coevaporate 3x with DCM.
FmocHN
Figure imgf000056_0001
Λ Column
\ 70%
DCM HO v S v NHFmoc four steps
Dissolve thiol in DCM. Add 1 eq of activated disulfide. Stir 30 min. TLC 1:1 Hex:EtOAc. Chrom.4:l to 2:l to 1:1.
FmocHN^ ^ ^S' ^ ^OH piperidine
Piperidine active
H( V Extr
IH,
[00163] Dissolve Fmoc protected alkoxyamine in THF. Add piperidine (100 miroliters for 40 mgs.). Stir 5-15 min. Remove solvent, then triturate with hexanes to remove fulvene byproduct. Dry under vacuum and store product as a lOOmM stock in methanol. See notebooks 23 and 41 for more detailed protocols and NMR.
[00164] 4. Synthesis of Bromoacetamide linker: BocHN'
Figure imgf000057_0001
Dissolve 1 eq. of bromoacetic acid in a small amount of ether. Chill on ice. Add 1 eq. of isobutyl chloroformate and 1 eq. of N-methyl morpholine. Remove N-methyl morpholine HCl precipitate by filtration into a flask cooled to 0C and wash with ether. Add 1 eq. of mono-Boc protected cystamine as a 1M solution in DCM. Monitor reaction by TLC, upon completion remove solvent and chromatograph with 2:1 hexanes/ethyl acetate.
[00165] 5. Synthesis of MTSPA
[00166] Sodium Methanesulfmate (tech grade, 85%) Aldrich 43,306-3 lOg for $50
Figure imgf000057_0002
MW 102 MW 32 MW 134 MTS-Na
Sulfur (powder) Aldrich 41,498-0 50g for $26
2g Sodium Methanesulfmate (MW 102, 17mmol based on 85% purity) [00167] 0.55g Sulfur (MW 32, 17 mmol)
[00168] (JOC 53 1988 p.401)
[00169] Combine Sodium Methanesulfmate and Sulfur in 60 mL on MeOH (reagent grade) and heat to reflux. Reflux for 1 hour, at which point the sulfur will have dissolved to yield a hazy solution. Let cool to room temperature and filter through Celite. Remove methanol in vacuo, and recrystallize from approximately 50 mL hot EtOH. For the recrystallization, there will be some insoluble material that must be removed by hot filtration through celite. Isolate approximately 1.4g, 60%, from first crop, second crop possible. IH NMR: singlet at 3.36ppm (D20). Used internal std. to confirm that all sodium bromide has been removed.
Figure imgf000058_0001
MW 134 M 219 MW 250
3-Bromopropylamine Hydrobromide Aldrich B7,980-3 lOOg for $86
2.8g MTS-Na (MW 134, 21mmol)
4.6g Bromopropylamine-HBr (MW 219, 21mmol) [00170] Combine reagents in 40mL of EtOH and heat at reflux for 6 hours (this is probably complete much faster than 6 hours). Let cool, filter to remove NaBr and wash with cold EtOH (Caution: product may crystallize out with sodium bromide). Concentrate filtrate, recrystallize from EtOH. Isolate approximately 60% (unoptimized). [00171] 6. Synthesis of Thiopropylamine Linker N-Boc aminoethanethiol Fluka 15303
- ftr ,NH2.HBr + BocHNN BocHN^^v.
*SH S'
MW 250 MW 177 MW 266
0.5g MTSPA-HBr (MW 250, 2mmol)
0.35g NBoc Aminoethanethiol (MW 177, 2mmol)
0.4mL DIEA (MW 129, 2.2mmol)
50 mL DCM
[00172] Dissolve MTSPA in 40 mL of DCM with 0.4mL DIEA (will dissolve slowly, sonication helps. Slight insoluble haze may be trace of NaBr from previous step). Dissolve N-
Boc aminoethane thiol in 10 mL DCM and add dropwise over 5 minutes to the stirred solution of MTSPA. Check by TLC after 10 minutes (5% MeOH in DCM with a few drops of TEA) to see a single spot, RF 0.3, with slight UV activity and strong ninhydrin response.
[00173] Filter reaction through Celite to remove insoluble materials. Remove solvent in vacuo and dissolve residue in 5 mL of 1M NaHSO4. Wash twice with 10 mL EtOAc, then cool aqueous portion on ice and raise pH to 11 with 5M NaOH. Extract twice with 10 mL
DCM, wash organics with 10 mL brine and then dry organics with Na2SO4. Concenfrate and dry under vacuum, isolate approximately 85% yield colorless oil. [00174] B. General description of Syntheses of Exemplary Classes of Compounds and Libraries of Compounds:
[00175] 1. Carboxylic acid derived monophores
Figure imgf000059_0001
R1-C02H
BocHN.
Figure imgf000059_0002
[00176] Synthesis of acid derived disulfide library: 260 μMols of 594 carboxylic acids were acylated in parallel with 130 μMol equivalents of 4-hydroxy-3-nitro-benzophenone on polystyrene using DIC in DMF. After 4 hours at room temperature, the resin was rinsed with DMF (2x), DCM (3x), and THF (lx) to remove uncoupled acid and DIC. The acids were cleaved from the resin via amide formation with 66 μMols of mono-boc protected cystamine in THF. After reaction for 12 hours at room temperature, the solvent was evaporated and the boc group was removed from the uncoupled half of each disulfide using 80% TFA in DCM. 530 (89%) acid derived disulfides passed Q.C. by LCMS.
[00177] 2. Isocyanate and thioisocyanate derived monophores.
'S „/~ 'NH2
R1— N=C=O H H
,NH, or + BocHN'
THF TFA S i— N=S=θ u -NH,
H H [00178] 10 μMols of 64 isocyanates and 120 isothiocyanates were coupled in parallel withlθ.5 μMols of mono-boc protected cystamine in THF. After reaction for 12 hours at room temperature, the solvent was evaporated and the boc group was removed from the uncoupled half of each disulfide using 50% TFA in DCM. 58 (91%) isocyanate derived disulfides and 94 (78%) isothiocyanate derived disulfides passed Q.C. by LCMS.
[00179] 3. Sulfonyl Chloride derived monophores
Figure imgf000060_0001
[00180] 10 μMols of 66 sulfonyl chlorides were coupled with 10.5 μMols of mono-boc protected cystamine in THF (2% diisopropyl ethyl amine) in the presence of 15 milligrams of poly(4-vinyl chloride). After 48 hours the poly(4-vinyl chloride) was removed via filtration and the solvent was evaporated. The boc group was removed from the uncoupled half of each disulfide using 50% TFA in DCM. 60 (91%) sulfonyl chloride derived disulfides passed Q.C. by LCMS. [00181] 4. Aldehyde and Ketone derived monophores.
Figure imgf000060_0002
[00182] Synthesis of ketone and aldehyde derived disulfide libraries: 10 μMols of 259 aldehydes and 225 ketones were coupled in parallel with 10.5 μMols of HO(CH2)2SS(CH2)2ONH2 in 1:1 methanolxhloroform (2% AcOH) for 12 hours at room temperature to yield the oxime product. 259 (100%) aldehyde disulfides and 189 (84%) ketone derived disulfides passed Q.C. by LCMS. [00183] 5. Phenol derived monophores
Figure imgf000061_0001
[00184] Synthesis of phenol derived libraries: lOμmol each of 206 phenols were dissolved in 0.5mL DMF. An aqueous solution of 0.8 M Cs2C03 (12.5μL) was added followed by a solution of the 10 μmol of the bromoacetamide linker in 12.5 μL DMF. Reactions were sealed and heated at 40°C for 15hrs. Products were isolated by diluting reactions with 2mL DCM, washing with ImL 1M NaOH, washing with brine and drying over sodium sulfate. The Boc protecting group was removed by addition of 2M HCl in ether and the HCL salts of the amines were obtained after evaporation of solvents.
[00185] 6. Synthesis of Methylthiosulfonate analogs (MTS)
Figure imgf000061_0002
MTSEA
[00186] Dissolve methyl thiosulfonate ethyl amine (0.25 mmol, 59 mg) (synthesized in the same manner as MTSPA, described above, or purchased from Toronto Research Chemicals) in 4mL dichloromethane with 2 equivalents of diisopropylethyl amine. In a separate vial, combine 0.25mmol of the carboxylic acid, 0.3 mmol of EDC and 0.3 mmol of HOBt. Add the solution of MTSEA and DIEA in DCM to the mixture of carboxylic acid with EDC and HOBt and stir. Monitor by HPLC, the coupling reaction is typically complete within 2 hrs. To isolate product first wash the organic solution with water, then with 1M aqueous NaHSO4 then with brine. Dry the organic phase with sodium sulfate and remove solvent by rotary evaporation. Products can be further purified by reverse phase preparative HPLC.
[00187] C. Generation of Building Block Diversity: As discussed above, a variety of building blocks can be used to generate the tethering reagents of the invention. For example, a number of commercially available bifunctional amino acids, as shown directly below, are available for use in the present invention. It will be appreciated, however, that the building blocks to be used in the invention are not limited to these particular reagents. Additionally, these commerically available reagents can be subsequently modified to generate "customized" reagents.
2H
Figure imgf000062_0001
[00188] Although a variety of inventive tethering reagents and libraries of reagents can be prepared using commercially available building blocks, it is also possible to "customize" these building blocks, or alternatively, develop building blocks for the development of further "customized" tethering reagents.
[00189] As but one example for the possibility of diversification, the addition of even a single additional synthetic step prior to the installation of the tether or "nub" ("1 + Nub") can dramatically increase the number of new compounds accessible from even simple starting materials. Even multistep syntheses can be considered, provided the diversity element is installed in the penultimate step. Examples of such "1 + nub," "2 + nub," etc. syntheses starting from L-proline are illustrated in one embodiment, as shown directly below:
Install tether or "nub"
Figure imgf000063_0001
"2 + nub"
Figure imgf000063_0002
[00190] It will be appreciated that the example of the constrained amino acid described above can be further modified (for example via C- or N-side modifications as described in more detail herein) to generate additional diversity in the tethering reagents and libraries described herein. Constrained amino acids in certain embodiments are utilized for their precedence in biologically active molecules and theoretical considerations (fewer rotational degrees of freedom, resist hydrophobic collapse, positional and stereochemical isomers can sample different regions of conformational space, etc.). A general schematic for the N- and C-side modification of a constrained amino acid is illustrated directly below: N-side Modification C-side Modification
Figure imgf000064_0001
reaction of template with a
Constrained reaction of template with variety of diverse sulfonyl amino acids a variety of diverse amines chlorides, isocyanates and carboxylic acids
[00191] Exemplary constrained amino acid blocks include, but are not limited to:
H2N, Λ:θ2H H
Figure imgf000064_0002
Figure imgf000064_0003
Trifunctional building blocks were also considered advantageous, since the additional point of modification can allow 1) the synthesis of additional regioisomers, 2) combinatorial elaboration/refinement of a monophore hit, and 3) a potential site for recombination with other monophore hits. The latter point may have particular utility with tethering, since hits obtained from different Cys mutants will by definition have their recombination nubs improperly oriented. Few constrained trifunctional building blocks are commercially available. The reagents trαrø-hydroxyproline, and R- and S-piperazine-2-carboxylic acid were available, and this list was supplemented with the unconstrained amino acids D- and L- 2,3-diaminopropionic acid (DAP), Asn, Gin, and Tyr as illustrated in the figure, below.
Figure imgf000064_0004
Hz
Figure imgf000064_0005
[00192] 1. N-side modifications [00193] Selection of Reagents for "N-side" Modifications. Both the N-terminal and C- terminal sides of a constrained amino acid can be employed for the incorporation of diversity elements. Approximately 200 isocyanates and 100 sulfonylchlorides are available in reasonable quantity commercially, and these sets can be readily examined by simple inspection to select reagents. Just over 250 carboxylic acids were selected. [00194] Exemplary Core Scaffolds. Many constrained amino acid scaffolds were converted into common intermediates for tethering libraries using the scheme illustrated below. Most of these were prepared in 25 mmol quantity, which is sufficient for all 250 planned N-side modifications. [00195] Scaffold synthesis scheme:
Figure imgf000065_0001
[00196] Scaffolds synthesized for first 1+Nub libraries. Shown below are examples of exemplary core scaffolds prepared in sufficient quantity for library synthesis. In most cases, these products were purified to homogeneity by flash chromatography prior to library synthesis.
Figure imgf000066_0001
Figure imgf000066_0002
Figure imgf000066_0003
Figure imgf000066_0004
[00197] Library preparation: synthesis protocols. As each scaffold is prepared it will be modified in the same fashion with the same set of building blocks. There is significant efficiency gained in this process, since SOPs developed for the first set of scaffolds can be used in subsequent experiments without modification. The Tecan was programmed in several different configurations before a satisfactory arrangement was found. This method accommodates up to 66 N-side diversity elements and 2 core scaffolds on the deck at one time. There is one quadrant that is not occupied by starting materials and is the only point where common reagents are added.
[00198] AU core scaffolds were modified with the N-side diversity inputs to prepare well over 5,000 new monophores. Reactions were performed using EDC/HOBt chemistry in 8:1 DCM/DMF.
[00199] Library Purification: An efficient liquid-liquid extraction procedure suitable for semi-automation on a Tecan robotic workstation was devised. A program specific for the 1+Nub chemistry was developed, and is shown schematically, below. In this method, crude reaction products (in 8/1 DCM/DMF) are first treated with 1 mL of 0.25 M aqueous HCl. The vials are then vigorously stirred on a vortex shaker to completely intermix the aqueous and organic layers.
[00200] The vial is allowed to stand, and then the organic (bottom) layer is transferred to a new vial. This solution is then treated with saturated aqueous sodium bicarbonate, and the agitation procedure repeated. A 24-well deep well filter plate is then charged with anhydrous Mg2S0 and placed over a rack of 24 tared, bar-coded vials. The final organic layer is dispensed into the filter plate and allowed to drip into the tared vials. A 1 mL DCM wash is added to the filter plate, and the combined filtrates are evaporated to dryness to complete the semi-automated work-up. Boc protection on the cystamine linker is removed with HCl/Dioxane and the vials concentrated to dryness again. All library members are characterized by LCMS; in some cases approximately 10 % of the library is also analyzed by Η NMR. With hydrophobic monophores, this method removes most of the reagents and failure products and affords good recovery of the desired product. Hydrophilic monophores and monophores with ionizable functional can require HPLC purification as some are removed in the extraction process. Regardless, the liquid-liquid extraction method is suitable for the majority of the compounds prepared.
[00201] 2. "C-Side" Libraries
[00202] "C-side" modifications. C-side modifications consist of the condensation of a highly diverse set of amines with conformationally-constrained core scaffolds bearing free carboxylic acids (see below). The chosen amines comprise 293 inputs that were selected based upon the diversity of functionality that they display.
Figure imgf000067_0001
[00203] Scaffold Synthesis. A procedure was devised that permits the synthesis of C-side core scaffolds in the absence of protecting group chemistry, eliminating as much as three synthetic steps. As shown in the following scheme, the carboxylic acid tethering linker is converted to its acyl chloride with Vilsmeier reagent, and then added to an ice-cold suspension of excess amino acid in DCM/TEA. This procedure worked for most of the constrained amino acids.
Figure imgf000068_0001
[00204] Shown in the figure below are the core scaffolds that were prepared for C-side libraries:
Figure imgf000068_0002
Figure imgf000068_0003
Figure imgf000068_0004
Figure imgf000069_0001
Figure imgf000069_0002
[00205] Exemplary Amine Reacations. Many of the amines we wished to condense with the above scaffolds contain free hydroxyls, carboxylates, and other functionality that can afford undesired side-products if the amine were simply coupled to a core scaffold using a conventional activating agent. Alternatively, a preformed active ester can often react preferentially with the desired amine and thus minimize side-product formation. Pentafluorophenyl (pFp) esters were first tried since they are often isolated as crystalline solids yet are quite reactive. In model reactions, a representative -OpFp ester was used to acylate a cross-section of amines. Although, products were found, many reactions were incomplete (even after 24 h). Addition of pyridine, DMAP, etc. had only marginal impact on product yields. Alternatively, activation of the acid with Vilsmeier reagent followed by freatment with the same amine set led to a good conversion of products in most cases. AU the amines were readily converted to products except for the indicated aniline as shown in the figure, below. All the C-side libraries were prepared using the Vilsmeier chemistry.
Figure imgf000069_0003
Y NH2
Figure imgf000069_0004
Figure imgf000069_0005
Figure imgf000069_0006
[00206] 3. Other Diversified Scaffolds: As described above, it is also possible to use additional diversified building blocks for the tethering reagents of the invention. For example, motifs that occur frequently and are well represented in a cross-section of therapeutic areas are heterocycles containing one or two heteroatoms, such as pyridines, thiazoles, oxazoles, pryimidines, etc. Another ubiquitous motif was tertiary amines. Exemplary syntheses for these fragments of interest is described in more detail below. [00207] Synthesis of Heterocycles
[00208] As much as possible, chemistries are chosen that are flexible such that simple variations can afford more than one class of building block. Carboxylic acids are common synthons for the synthesis of heterocycles, and simple derivatives of this functional group can be combined with an elecfrophile to create a heterocycle. This is shown schematically, below:
Figure imgf000070_0001
Heterocycles:
Figure imgf000070_0002
[00209] These heterocycles are prepared as building blocks for subsequent derivatization with other diversity elements. Alternatively, the chemistries shown above can be used to make many subtle variations of each heterocycle as exemplified below and herein. [00210] Synthesis of Thiazoles. . A modified Hantzsch procedure has been employed in the synthesis of several thiazoles. The thiazoles were largely designed based upon the most common form of appearance of this motif in the MDDR. Appropriate amino acids were converted to thioamides in two steps, followed by cyclodehydration with the appropriate bromoketone:
Figure imgf000071_0001
2) TFAA, pyridine
3) LiOH
Figure imgf000071_0002
[00211] Several thiazole amino acid derivatives were prepared, encompassing a cross- section of conformational constraint (see below), and these were used to prepare a library as described in the working examples.
Figure imgf000071_0003
[00212] Synthesis of pyridones and pyrrolidinones. Using aza-annulation chemistry, a common intermediate was employed for the synthesis of two piperidones and a pyrrolidone in good yield (see below). This chemistry is sufficiently flexible to permit the synthesis of bicyclic analogs of these motifs, some of which are recognized beta-turn mimetics. During the optimization of the chemistry it was found that some protecting group manipulations (ester hydrolysis) led to the formation of significant by-products derived from the disulfide of the tether linker. The optimized route used O-allyl protection, which could be efficiently deprotected in the presence of the disulfide using Pd(PPh3)4. These were used to prepare "C- side" libraries as described previously.
Figure imgf000072_0001
[00213] Substituted piperazines. Piperazines are the most common motif in the CMC and MDDR, and several N-side Nub+1 libraries have already been prepared from piperazine scaffolds. Shown below is a common intermediate that can be used in the preparation of three piperazine motifs (and their regioisomers), including forms which will ultimately display a basic amine (Boc- protected), a tertiary amine (N-methyl) and an amide (N-acetyl). These three motifs represent fragments of the most common forms of derivatization for this core scaffold. Each of these can be made from the indicated Boc/Fmoc intermediate. After much experimentation, we have devised an efficient two step procedure for the preparation of this intermediate, and over 50 g are currently in-house. Each piperazine motif will be systematically prepared and derivatized using the "Go To" amine set.
Figure imgf000072_0002
[00214] Oxazoles. Oxazoles are also a common motif. A variety of oxazoles were prepared from conformationally constrained amino acids and serine using the route shown below:
Figure imgf000072_0003
[00215] The following scaffolds were synthesized:
Figure imgf000073_0001
Figure imgf000073_0002
[00216] These intermediates are converted to tethering monophores using a route similar to that previously described for the "C-side" 1+Nub chemistry. [00217] Scaffold Permutation
[00218] The above examples involved making a unique or unusual building block that could be used as an intermediate for monophore synthesis. The following examples illustrate chemistries that lead to a unique variant of the chemotype.
[00219] Preparation of tertiary amines. A solid-phase synthesis route was adapted for the preparation of tertiary amines. Briefly, immobilization of the cysteamine linker to BAL resin provides a common intermediate for a number of different syntheses. In the present example, the resin-bound tether linker is acylated with an amino acid, the amino acid is then deprotected and then alkylated with an appropriate aldehyde to prepare the desired tertiary amine. Arylation is also possible using established methods. The procedure for tertiary amine synthesis is shown schematically, below:
Figure imgf000073_0003
[00220] Preparation of aminothiazoles. Aminothiazoles are being prepared, and their synthesis utilizes the same resin-bound linker intermediate employed for the tertiary amine synthesis. Approximately 400 of these compounds have been prepared and are being purified by HPLC prior to release into the monophore collection.
Figure imgf000074_0001
Resin
Figure imgf000074_0002
Figure imgf000074_0003
2) TFA
Figure imgf000074_0004
Figure imgf000074_0006
[00221] D. Exemplary Library Syntheses:
[00222] Example 1 Library 000004 consists of 484 peptidomimetic compounds connected to the cystamine-derived tethering linker. This library consists of four conformationally constrained amino acid "scaffolds" that were acylated with 121 different carboxylic acids. General formula for the library is as follows:
Figure imgf000074_0005
ds Name: -Pro Isonipecotic acid tr omethyl)cyclo hexane carbc jxylic acid where R' is defined as for R5 and R6, as described generally herein.
[00223] Example 2:. Library 000005 consists of 453 peptidomimetic compounds connected to the cystamine-derived tethering linker. This library consists of four conformationally-constrained amino acid "scaffolds" that were acylated with 121 different carboxylic acids. General formula for the library is as follows:
Figure imgf000075_0001
Scaffolds Name: frans-L-Hyp Nipecotic acid L-Ala D-Ala
where R' is defined as for R5 and R6, as described generally herein.
[00224] Example 3. Library 000006 consists of 453 peptidomimetic compounds connected to the cystamine-derived tethering linker. This library consists of four conformationally-consfrained amino acid "scaffolds" that were acylated with 121 different carboxylic acids. General formula for the library is as follows:
Figure imgf000075_0002
Scaffolds: Name: c/s-4-aminocyclo- L.Pjp L.Tjc c/s-2-aminocyclo- hexanecarboxylic acid hexanecarboxylic acid
where R' is defined as for R5 and R , as described generally herein. [00225] Example 4:. Library 000007 consists of 681 peptidomimetic compounds connected to the cystamine-derived tethering linker. This library consists of six conformationally-constrained amino acid "scaffolds" that were acylated with 121 different carboxylic acids. General formula for the library is as follows:
Figure imgf000076_0001
where R' is defined as for R5 and R , as described generally herein.
[00226] Example 5: Library 000014 was prepared from four conformationally- constrained amino acid "scaffolds" that were used to acylated 293 diverse primary and secondary amines (1172 reactions). After eliminating compounds that failed QC, 690 compounds were released. General formula for the library is as follows:
acids,
Figure imgf000076_0002
tc.
Scaffolds:
Figure imgf000076_0003
[00227] Example 6: Library 000017 was prepared from 10 conformationally-consfrained amino acid "scaffolds" that were used to acylate 220 diverse primary and secondary amines (approx. 2200 reactions). After eliminating compounds that failed QC, 833 compounds were released. General formula for the library is as follows: Scaffolds Boc*
Figure imgf000077_0001
Figure imgf000077_0002
[00228] Example 7: Library 000018 was prepared from 9 conformationally-constrained amino acid "scaffolds" that were used to acylate 220 diverse primary and secondary amines (approx. 2000 reactions). After eliminating compounds that failed QC, 811 compounds were released. General formula for the library is as follows:
Scaffolds "Cθ2H
Figure imgf000077_0003
Figure imgf000077_0004
[00229] Example 8: Library 000016 was prepared from five thiazole core scaffolds, that were used to acylated 220 diverse primary and secondary amines (1100 reactions). 750 of these passed QC and were added to the screening collection. ids,
Figure imgf000078_0001
Figure imgf000078_0002
[00230] E. Identification: Following tethering the ligand to a TBM, the ligands bound to a target can be readily detected and identified by mass spectroscopy (MS). MS detects molecules based on mass-to-charge ratio (m/z) and thus can resolve molecules based on their sizes (reviewed in Yates, Trends Genet. 16: 5-8 [2000]). A mass spectrometer first converts molecules into gas-phase ions, then individual ions are separated on the basis of m/z ratios and are finally detected. A mass analyzer, which is an integral part of a mass spectrometer, uses a physical property (e.g. electric or magnetic fields, or time-of-flight [TOF]) to separate ions of a particular m/z value that then strikes the ion detector.
[00231] Mass spectrometers are capable of generating data quickly and thus have a great potential for high-throughput analysis. MS offers a very versatile tool that can be used for drug discovery. Mass spectroscopy may be employed either alone or in combination with other means for detection or identifying the organic compound ligand bound to the target. Techniques employing mass spectroscopy are well known in the art and have been employed for a variety of applications (see, e.g., Fitzgerald and Siuzdak, Chemistry & Biology 3: 707- 715 [1996]; Chu et al, J. Am. Chem. Soc. 118: 7827-7835 [1996]; Siudzak, Proc. Natl. Acad. Sci. USA 91: 11290-11297 [1994]; Burlingame et al, Anal. Chem. 68: 599R-651R [1996]; Wu et al, Chemistry & Biology 4: 653-657 [1997]; and Loo et al, Am. Reports Med. Chem. 31: 319-325 [1996]).
[00232] Other techniques that may find use for identifying the organic compound bound to the target molecule include, for example, nuclear magnetic resonance (NMR), capillary electrophoresis, X-ray crystallography, and the like, all of which will be well known to those skilled in the art.

Claims

1. A compound having the structure (I):
(I)
wherein A is -S(CH2)PRA1 or-SCO)^, wherein p is 1-5, RA1 is -NRA3RM; ORA3; SRA3; -NHCOR^; -NHCONRA3RA4; -NRA3RA4RA5+X', wherein X is a halogen; -COOR^; CONRA3RA4; -SOsR^; -OPOsR^; -SO^; and wherein R^ is an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, and each occurrence of R*3, RA4, and RA5 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety; n is 0-5;
L is a moiety having one of the structures:
Figure imgf000079_0001
*s JLAa H« I , γ Rlγ ll V ' a ^
Figure imgf000079_0002
each occurrence of R1 and R2 is independently hydrogen, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, or wherein R1 and R2 taken together are a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl moiety; whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted,
Figure imgf000080_0001
with the proviso that compounds having the structure: H , where RA1 is NRA3RA4 or NRA3RA4RA5X", wherein each occurrence of RA3, RA4 and RA5 is hydrogen or a protecting group, and X is a halogen; and R1 is one of the following:
Figure imgf000080_0002
are excluded.
2. The compound of claim 1, wherein L is one of the following structures:
Figure imgf000080_0003
3. The compound of claim 1, wherein L1 W nN represents one of the structures:
Figure imgf000081_0001
wherein r is 1 or 2; t is 0, 1 or 2; and R 2 is an alkyl, heteroalkyl, aryl, heteroaryl, (alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety.
^ S
The compound of claim 1, wherein W n represents one of the structures:
Figure imgf000081_0002
wherein r is 1 or 2; and R )A^2 i :s an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, (alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety.
5. The compound of claim 4, whereinR^ is methyl or phenyl
Figure imgf000082_0001
The compound of claim 1, wherein one or both of R1 or R2 is m or D
or wherein R1 and R2 taken together form a cyclic moiety having the
Figure imgf000082_0002
wherein B-D, D-E, E-G, G-J, two or more occurrences of J, and J-B are each independently joined by a single or double bond as valency and stability permit, wherein B is N, CH or C, D is -NRD-, =N-, -O-, -CHRD-, or =CRD-, E is -NRE-, =N-, -O-, -CHRE-, or =CRE-, G is -NRG-, =N-, -0-, -CHRG-, or =CRG-, each occurrence of J is independently - NRJ-, =N-, -O-,-CHRJ-, or =CRJ-, m is 0-4 and p is 0-4, each occurrence of R3, R4, RD, RE, RG and RJ is independently hydrogen, a protecting group, -(CR7R8)qNR5R6, -(CR7R8)qOR5, -(CR7R8) qSR5, -(CR7R8)q(C=O)R5, - (CR7R8)q(C=O)OR5; -(CR7R8)q(C=O)NR5R6, -(CR7R8)qS(O)2R5, -(CR7R8)qNR5(C=O)R6, - (CR7R8)qNR5(C=O)OR6,- (CR7R8)qS(O)2NR5R6, -(CR7R8)qNR5S(0)2R6, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, q is 0-4; and each occurrence of R5, R6, R7 and R8 is independently hydrogen, a protecting group, or an aliphatic, heteroalipahtic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroalipahtic)aryl, or -(heteroaliphatic)heteroaryl moiety; whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
7. The compound of claim 1, wherein L is
Figure imgf000082_0003
R3y^ or R4 ; wherein m is 0-4, p is 0-4, D is CHRD or NRD, G is CHRG or NRG, and each occurrence of J is independently CHRJ or NRJ, wherein each occurrence of RD, RE, RG, RJ, R3, and R4 is independently hydrogen, a protecting group, -(CR7R8)qNR5R6, -(CR7R8)qOR5, (CR7R8)qSR5, -(CR7R8)q(C=0)R5, -(CR7R8)q(C=O)NR5R6, -(CR7R8)qS(0)2R5, - (CR7R8)qNR5(C=O)R6, -(CR7R8)qS(O)2NR5R6, -(CR7R8)qNR5S(O)2R6, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, wherein q is 0-4; and wherein each occurrence of R5 and R6 is independently hydrogen, a protecting group, or an aliphatic, heteroalipahtic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroalipahtic)aryl, or - (heteroaliphatic)heteroaryl moiety; whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
Figure imgf000083_0001
The compound of claim 1, wherein L is o and R is one of the structures:
Figure imgf000083_0002
I
R 2'
The compound of claim 1, wherein L is ό and one or both of R1 and R2 is
Figure imgf000084_0001
or R4 , or wherein R1 and R2 taken together with N form a cyclic
structure:
Figure imgf000084_0002
; wherein N-D, D-E, E-G, G-J, two or more occurrences of J, and J-N are each independently joined by a single or double bond as valency and stability permit, wherein D is -NRD-, =N-, -O-, -CHRD-, or =CRD-, E is -NRE-, =N-, -O-, -CHRE-, or =CRE-, G is -NRG-, =N-, -O-, -CHRG-, or =CRG-, each occurrence of J is independently -NRJ-, =N-, -O-,-CHRJ-, or =CRJ-, m is 0-4 and p is 0-4, each occurrence of R , R , R , R , R and R is independently hydrogen, a protecting group, -(CR7R8)qNR5R6, -(CR7R8)qOR5, -(CR7R8)qSR5, -(CR7R8)q(C=0)R5, - (CR7R8)q(C=O)OR5; -(CR7R8)q(C=0)NR5R6, -(CR7R8)qS(O)2R5, -(CR7R8)qNR5(C=O)R6, - (CR7R8)qNR5(C=O)OR6,- (CR7R8)qS(O)2NR5R6, -(CR7R8)qNR5S(O)2R6, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, q is 0-4; and each occurrence of R5, R6, R7 and R8 is independently hydrogen, a protecting group, or an aliphatic, heteroalipahtic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroalipahtic)aryl, or -(heteroaliphatic)heteroaryl moiety; whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
10. The compound of claim 1, wherein L is
Figure imgf000084_0003
and one or both of R1 and R2 is a moiety having one of the following structures, or wherein R1 and R2 taken together with N form a cyclic moiety having one of the following structures:
Figure imgf000085_0001
. The compound of claim 1 , wherein L is R1 has one of the following structures:
x DXA X 1 H
12. The compound of claim 1, wherein L is Rγ o v 5 and R1 has one of the following structures:
13. The compo
Figure imgf000086_0001
und of claim 1, wherein L is 5 and R has one of the following structures:
Figure imgf000086_0002
14. The compound of claim 1, wherein L is Rγ o v 5 and R1 has one of the following structures:
Figure imgf000086_0003
. The compound of claim 1, wherein L is , and R1 has one of the following structures:
Figure imgf000087_0001
16. The compound of claim 1, wherein L is
Figure imgf000087_0002
, and R1 is one of the following structures:
Figure imgf000087_0003
The compound of claim 1, wherein L is , and R1 is one of the following structures:
Figure imgf000088_0001
The compound of claim 1, wherein L is 5 and R1 and R2 are each independently hydrogen or a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl moiety optionally substituted with a substituted heteroaryl moiety.
19. The compound of claim 18, wherein the substituted heteroaryl moiety has one of the structures:
Figure imgf000088_0002
wherein R9 is -COO(R10), -CO(R10), -CO(NR10Rπ), -NΛ^-NR^COR11, -OR10, or -SR10, wherein each occurrence of R10 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted. 20. The compound of claim 19, wherein R1 and R2 represent one of the following structures:
Figure imgf000089_0001
wherein R9 is COOH or is CO(NR10Rn), wherein each occurrence of R10 and R11 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
21. A library of compounds comprising a plurality of compounds having the structure (I):
00
wherein A is -S(CH2)PRA1 or Sfpy L*2, wherein p is 1-5, RA1 is -NRA3RA4; OR^; SRA3; -NHCORA3; -NHCONRA3RA4; -NRA3RA4RA5+X", wherein X is a halogen; -COORA3; CONRA3RA4; -SO3RA3; -OPO3RA3; -SQzR 3; and wherein R^ is an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, and each occurrence of R 3, RA4, and RA5 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety; n is 0-5;
L is a moiety having one of the structures:
Figure imgf000090_0001
each occurrence of R1 and R2 is independently hydrogen, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, or wherein R1 and R2 taken together are a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl moiety; whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted
O
>A>.^ .S..^ .RA1 with the proviso that compounds having the structure: H , where RA1 is NRA3RA4 or NRA3RA4RA5X\ wherein each occurrence of RA3, RA4 and RA5 is hydrogen or a protecting group, and X is a halogen; and R1 is one of the following:
Figure imgf000090_0002
are excluded.
22. The library of claim 21, wherein L is one of the following structures:
Figure imgf000091_0001
23. The library of claim 21, wherein L* W nS represents one of the structures
Figure imgf000091_0002
wherein r is 1 or 2; t is 0, 1 or 2; and ^ is an alkyl, heteroalkyl, aryl, heteroaryl, (alkyl)aryl, -(alkylheteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety.
24. The library of claim 21 , wherein
Figure imgf000091_0003
represents one of the structures
Figure imgf000092_0001
wherein r is 1 or 2; and R >A2 is an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, (alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety.
25. The library of claim 24, wherein R^ is methyl or phenyl.
26. The library of claim 21, wherein one or both of R1 or R2 is
Figure imgf000092_0002
5 or
wherein R 1 and R 2 taken together form a cyclic moiety having the structure: )s J ') m , wherein B-D, D-E, E-G, G-J, two or more occurrences of J, and J-B are each independently joined by a single or double bond as valency and stability permit, wherein B is N, CH or C, D is -NRD-, =N-, -O-, -CHRD-, or =CRD-, E is -NRE-, =N-, -O-, -CHRE-, or =CRE-, G is -NRG-, =N-, -O-, -CHRG-, or =CRG-, each occurrence of J is independently - NRJ-, =N-, -O-,-CHRJ-, or =CRJ-, m is 0-4 and p is 0-4, each occurrence of R , R , R , R , R and R is independently hydrogen, a protecting group, -(CR7R8)qNR5R6, -(CR7R8)qOR5, -(CR7R8))qSR5, -(CR7R8)q(C=O)R5, - (CR7R8)q(C=O)ORs; -(CR7R8)q(C=O)NR5R6, -(CR7R8)qS(O)2R5, -(CR7R8)qNR5(C=O)R6, - (CR7R8)qNR5(C=O)OR6,- (CR7R8)qS(O)2NR5R6, -(CR7R8)qNR5S(O)2R6, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, q is 0-4; and each occurrence of Rs, R6, R7 and R8 is independently hydrogen, a protecting group, or an aliphatic, heteroalipahtic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroalipahtic)aryl, or -(heteroaliphatic)heteroaryl moiety; whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
27. The library of claim 21, wherein L is
Figure imgf000093_0001
and R1 is
R3γ^ or R4 ; wherein m is 0-4, p is 0-4, D is CHRD or NRD, G is CHRG or NRG, and each occurrence of J is independently CHRJ or NRJ, wherein each occurrence of RD, RE, RG, RJ, R3, and R4 is independently hydrogen, a protecting group, -(CR7R8)qNR5R6, -(CR7R8)qOR5, - (CR7R8)qSR5, -(CR7R8)q(C=O)R5, -(CR7R8)q(C=O) R5R6, -(CR7R8)qS(O)2R5, - (CR7R8)qNR5(C=0)R6, -(CR7R8)qS(O)2 R5R6, -(CR7R8)qNR5S(O)2R6, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, wherein q is 0-4; and wherein each occurrence of R5 and R6 is independently hydrogen, a protecting group, or an aliphatic, heteroalipahtic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroalipahtic)aryl, or - (heteroaliphatic)heteroaryl moiety; whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
28. The library of claim 21, wherein L is
Figure imgf000093_0002
2
Figure imgf000094_0001
. The library of claim 21, wherein L is and one or both of R1 and R2 is
AA ~~ ' m or R R4 , or wherein R1 and R2 taken together with N form a cyclic ■A structure: m ; wherein N-D, D-E, E-G, G-J, two or more occurrences of J, and J-N are each independently joined by a single or double bond as valency and stability permit, wherein D is -NRD-, =N-, -O-, -CHRD-, or =CRD-, E is -NRE-, =N-, -O-, -CHRE-, or =CRE-, G is -NRG-, =N-, -O-, -CHRG-, or =CRG-, each occurrence of J is independently -NRJ-, =N-, -O-,-CHRJ-, or =CRJ-, m is 0-4 and p is 0-4, each occurrence of R3, R4, RD, RE, RG and RJ is independently hydrogen, a protecting group, -(CR7R8)qNR5R6, ~(CR7R8)qOR5, -(CR7R8)qSR5, -(CR7R8)q(C=0)R5, - (CR7R8)q(C=O)OR5; -(CR7R8)q(C=O)NR5R6, -(CR7R8)qS(O)2R5, -(CR7R8)qNR5(C=O)R6, - (CR7R8)qNR5(C=O)OR6,- (CR7R8)qS(O)2NR5R6, -(CR7R8)qNR5S(O)2R6, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, q is 0-4; and each occurrence of R5, R6, R7 and R8 is independently hydrogen, a protecting group, or an aliphatic, heteroalipahtic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroalipahtic)aryl, or -(heteroaliphatic)heteroaryl moiety; whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
R
30. The library of claim 21, wherein L is ° and one or both of R1 and R2 is a moiety having one of the following structures, or wherein R1 and R2 taken together with N form a cyclic moiety having one of the following structures:
Figure imgf000095_0001
Figure imgf000096_0001
The library of claim 21 , wherein L is R1 has one of the following structures:
Figure imgf000096_0002
32. The library of claim 21, wherein L is
Figure imgf000096_0003
, and R1 has one of the following structures:
33. The library
Figure imgf000096_0004
of claim 21, wherein L is , and R1 has one of the following structures:
Figure imgf000096_0005
34. The library of claim 21, wherein L is
Figure imgf000097_0001
structures:
Figure imgf000097_0002
The library of claim 21, wherein L is , and R1 has one of the following structures:
Figure imgf000097_0003
36. The library of claim 21, wherein L is
Figure imgf000097_0004
5 and R1 is one of the following structures:
Figure imgf000098_0001
37. The library of claim 21 , wherein L is "Υ o , and R1 is one of the following structures:
3
Figure imgf000098_0002
8. The library of claim 21, wherein L is , and R1 and R2 are each independently hydrogen or a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl moiety optionally substituted with a substituted heteroaryl moiety.
39. The library of claim 38, wherein the substituted heteroaryl moiety has one of the structures:
Figure imgf000099_0001
wherein R9 is -COO(R10), -CO(R10), -CO(NR10Rn), -NR^R'^-NR^COR11, -OR10, or -SR10, wherein each occurrence of R10 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted. 40. The library of claim 39, wherein R1 and R2 represent one of the following structures:
Figure imgf000099_0002
wherein R9 is COOH or is CO(NR10Rn), wherein each occurrence of R10 and R11 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic,. aryl, heteroaryl, ~(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
41. The library of claim 21, wherein the library comprises at least 5 members.
42. The library of claim 21, wherein the library comprises at least 20 members.
43. The library of claim 21, wherein the library comprises at least 100 members.
44. The library of claim 21, wherein the library comprises at least 500 members.
45. The library of claim 21, wherein the library comprises at least 1000 members.
46. The library of claim 21, wherein each member has a different molecular weight.
47. The library of claim 21, wherein each member has a mass that differs from another member by at least 5 atomic mass units.
48. The library of claim 21, wherein each member has a mass that differs from another member by at least 10 atomic mass units.
49. A method for ligand discovery comprising: contacting a target that comprises a chemically reactive group at or near a site of interest with a compound of claim 1 that is capable of forming a covalent bond with a chemically reactive group; forming a covalent bond between the target and the compound thereby forming a target-compound conjugate; and identifying the target compound conjugate.
PCT/US2002/014778 2001-08-07 2002-05-10 Disulfide and thiosulfonate ligands and libraries comprising these ligands WO2003014072A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002457814A CA2457814A1 (en) 2001-08-07 2002-05-10 Disulfide and thiosulfonate ligands and libraries comprising these ligands
NZ530811A NZ530811A (en) 2001-08-07 2002-05-10 Disulfide and thiosulfonate ligands and libraries comprising these ligands
JP2003519022A JP2004537594A (en) 2001-08-07 2002-05-10 Disulfide and thiosulfonate ligands, and libraries containing these ligands
EP02746365A EP1421063A1 (en) 2001-08-07 2002-05-10 Disulfide and thiosulfonate ligands and libraries comprising these ligands
IL15998302A IL159983A0 (en) 2001-08-07 2002-05-10 Disulfide and thiosulfonate ligands and libraries comprising these ligands
MXPA04001074A MXPA04001074A (en) 2001-08-07 2002-05-10 Disulfide and thiosulfonate ligands and libraries comprising these ligands.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US31072501P 2001-08-07 2001-08-07
US60/310,725 2001-08-07
US09/990,421 US6919178B2 (en) 2000-11-21 2001-11-21 Extended tethering approach for rapid identification of ligands
US09/990,421 2001-11-21
US10/121,216 2002-04-10
US10/121,216 US6998233B2 (en) 1998-06-26 2002-04-10 Methods for ligand discovery

Publications (1)

Publication Number Publication Date
WO2003014072A1 true WO2003014072A1 (en) 2003-02-20

Family

ID=27382591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/014778 WO2003014072A1 (en) 2001-08-07 2002-05-10 Disulfide and thiosulfonate ligands and libraries comprising these ligands

Country Status (7)

Country Link
EP (1) EP1421063A1 (en)
JP (1) JP2004537594A (en)
CA (1) CA2457814A1 (en)
IL (1) IL159983A0 (en)
MX (1) MXPA04001074A (en)
NZ (1) NZ530811A (en)
WO (1) WO2003014072A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202033B2 (en) 2002-03-21 2007-04-10 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
WO2007040968A2 (en) * 2005-09-30 2007-04-12 3M Innovative Properties Company Crosslinked polymers with amine binding groups
US7214487B2 (en) 1998-06-26 2007-05-08 Sunesis Pharmaceuticals, Inc. Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
JP2008510795A (en) * 2004-08-26 2008-04-10 アッパラオ・サティアム Novel biocleavable linker
US7544755B2 (en) 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
US7544754B2 (en) 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1576161A (en) * 1976-02-13 1980-10-01 Squibb & Sons Inc Proline derivatives and related compounds
EP0117693A2 (en) * 1983-02-25 1984-09-05 The Upjohn Company Enzyme-linked immunoassay, assay kits and pair-binding compounds
JPH08201958A (en) * 1995-01-24 1996-08-09 Konica Corp Silver halide photographic sensitive material and image forming method
WO1998052619A2 (en) * 1997-05-22 1998-11-26 Merck Patent Gmbh Peptide-coated implants and methods for producing same
WO1999049314A1 (en) * 1998-03-27 1999-09-30 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US6335155B1 (en) * 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
WO2002042773A2 (en) * 2000-11-21 2002-05-30 Sunesis Pharmaceuticals, Inc. An extended tethering approach for rapid identification of ligands

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1576161A (en) * 1976-02-13 1980-10-01 Squibb & Sons Inc Proline derivatives and related compounds
EP0117693A2 (en) * 1983-02-25 1984-09-05 The Upjohn Company Enzyme-linked immunoassay, assay kits and pair-binding compounds
JPH08201958A (en) * 1995-01-24 1996-08-09 Konica Corp Silver halide photographic sensitive material and image forming method
WO1998052619A2 (en) * 1997-05-22 1998-11-26 Merck Patent Gmbh Peptide-coated implants and methods for producing same
WO1999049314A1 (en) * 1998-03-27 1999-09-30 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US6335155B1 (en) * 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
WO2002042773A2 (en) * 2000-11-21 2002-05-30 Sunesis Pharmaceuticals, Inc. An extended tethering approach for rapid identification of ligands

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GRIVNAK, L. M. ET AL: "Thiosulfonic acids. XIX. Thiosulfonic acid esters containing hydrazide hydrazone groups", XP002209592, retrieved from STN Database accession no. 68:68584 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GRIVNAK, L. M. ET AL: "Thiosulfonic acids. XVII. Derivatives of carboxymethyl esters of thiosulfonic acids", XP002209593, retrieved from STN Database accession no. 68:21644 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; VODOLAZSKAYA, N. A. ET AL: "Antitumor activity of some esters of thiosulfonic acids, including the thio analogs and homologs of Myleran", XP002209594, retrieved from STN Database accession no. 66:36436 *
DOKL. AKAD. NAUK SSSR (1966), 170(5), 1081-3 *
ERLANSON DANIEL A ET AL: "Site-directed ligand discovery", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 17, 15 August 2000 (2000-08-15), pages 9367 - 9372, XP002199107, ISSN: 0027-8424 *
HANEFELD, WOLFGANG ET AL: "Oxidation of thiocarbamidates. 10..alpha.-Carbamoyl sulfoxides and sulfones. 2. Formation of thiosulfonates by hydrolysis of cyclic.alpha.-carbamoyl sulfoxides", LIEBIGS ANN. CHEM. (1986), (10), 1787-95, XP001093949 *
HOVINEN, JARI ET AL: "Novel solid supports for the preparation of 3'-derivatized oligonucleotides: introduction of 3'-alkylphosphate tether groups bearing amino, carboxy, carboxamido, and mercapto functionalities", TETRAHEDRON (1994), 50(24), 7203-18, XP002209588 *
ICHIKAWA, M. ET AL: "A mechanism-based affinity-labeling agent for possible use in isolating N-acetylglucosaminidase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001), 11(13), 1769-1773, XP002209589 *
JANDA, KIM D. ET AL: "Chemical selection for catalysis in combinatorial antibody libraries", SCIENCE (WASHINGTON, D. C.) (1997), 275(5302), 945-948, XP002209590 *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 12 26 December 1996 (1996-12-26) *
PROBL. POLUCH. POLUPROD. PROM. ORG. SIN., AKAD. NAUK SSSR, OTD. OBSHCH. TEKH. KHIM. 1967 (1967), 77-80 *
SPURA, ARMIN ET AL: "Biotinylation of substituted cysteines in the nicotinic acetylcholine receptor reveals distinct binding modes for.alpha.-bungarotoxin and erabutoxin a", JOURNAL OF BIOLOGICAL CHEMISTRY (2000), 275(29), 22452-22460, XP002209591 *
ZH. ORG. KHIM. (1967), 3(12), 2160-2 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214487B2 (en) 1998-06-26 2007-05-08 Sunesis Pharmaceuticals, Inc. Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
US7202033B2 (en) 2002-03-21 2007-04-10 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
JP2008510795A (en) * 2004-08-26 2008-04-10 アッパラオ・サティアム Novel biocleavable linker
WO2007040968A2 (en) * 2005-09-30 2007-04-12 3M Innovative Properties Company Crosslinked polymers with amine binding groups
WO2007040968A3 (en) * 2005-09-30 2007-09-07 3M Innovative Properties Co Crosslinked polymers with amine binding groups
US7544755B2 (en) 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
US7544756B2 (en) 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
US7544754B2 (en) 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
US7632903B2 (en) 2005-09-30 2009-12-15 3M Innovative Properties Company Crosslinked polymers with amine binding groups
US7671155B2 (en) 2005-09-30 2010-03-02 3M Innovative Properties Company Crosslinked polymers with amine binding groups
US7671154B2 (en) 2005-09-30 2010-03-02 3M Innovative Properties Company Crosslinked polymers with amine binding groups
KR101244125B1 (en) * 2005-09-30 2013-03-14 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Crosslinked polymers with amine binding groups

Also Published As

Publication number Publication date
NZ530811A (en) 2005-07-29
MXPA04001074A (en) 2004-07-08
EP1421063A1 (en) 2004-05-26
IL159983A0 (en) 2004-06-20
CA2457814A1 (en) 2003-02-20
JP2004537594A (en) 2004-12-16

Similar Documents

Publication Publication Date Title
US20120077711A1 (en) Novel Ligands and Libraries of Ligands
JP7169327B2 (en) Imido-based proteolytic modulators and related methods of use
EP1789416B1 (en) Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
CA2464094C (en) Methods for ligand discovery
US6998233B2 (en) Methods for ligand discovery
JP2006113077A (en) Extended tethering approach for rapid identification of ligand
CN117736134A (en) Compounds and methods for enhancing degradation of target proteins and other polypeptides by E3 ubiquitin ligases
CN111606970B (en) 1, 5-diazabicyclo [5,3,0] decarenone amino acid derivative and preparation method and application thereof
JP2019527672A (en) Library of various macrocyclic compounds and methods for their production and use
Vedejs et al. Solution-Phase Synthesis of a Hindered N-Methylated Tetrapeptide Using Bts-Protected Amino Acid Chlorides: Efficient Coupling and Methylation Steps Allow Purification by Extraction
EP1421063A1 (en) Disulfide and thiosulfonate ligands and libraries comprising these ligands
JP2019501188A (en) Library of heteroaryl-containing macrocycles and methods for making and using the same
CA2719579A1 (en) Methods of chemotype evolution
AU2002316090A1 (en) Disulfide and thiosulfonate ligands and libraries comprising these ligands
Boudjabi et al. Sulfahydantoins as Tripeptide Constraints: Synthesis and Structure of Chiral Substituted 3‐Oxo‐1, 2, 5‐thiadiazolidine 1, 1‐Dioxides
Marciniak et al. Development of novel PEX5-PEX14 protein-protein interaction (PPI) inhibitors based on an oxopiperazine template
ZA200400745B (en) Disulfide and thiosulfonate ligands and libraries comprising these ligands.
Abdildinova et al. Traceless solid-phase synthesis and β-turn propensity of 1, 3-thiazole-based peptidomimetics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE CH CY DE DK FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 159983

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002316090

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 530811

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004/00745

Country of ref document: ZA

Ref document number: 200400745

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2457814

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/001074

Country of ref document: MX

Ref document number: 2002746365

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003519022

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002746365

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 530811

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 530811

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2002746365

Country of ref document: EP